etoposide has been researched along with Lymphoma in 414 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 75 (18.12) | 18.7374 |
| 1990's | 118 (28.50) | 18.2507 |
| 2000's | 116 (28.02) | 29.6817 |
| 2010's | 71 (17.15) | 24.3611 |
| 2020's | 34 (8.21) | 2.80 |
| Authors | Studies |
|---|---|
| Kurumurthy, C; Narsaiah, B; Pamanji, R; Sambasiva Rao, P; Santhosh Kumar, G; Shanthan Rao, P; Veera Swamy, B; Velatooru, LR; Venkateswara Rao, J | 1 |
| Chiba, A; Ebisawa, K; Honda, A; Kurokawa, M; Masamoto, Y; Okazaki, H | 1 |
| Song, Y; Wang, J; Wang, Y; Wang, Z; Wu, L | 1 |
| Atalla, A; Costa, LJM; Duarte, FB; Leal, CTS; Neto, AEH; Pereira, J; Sabioni, BS; Tavares, RB | 1 |
| Ashkenazi, M; Avni, B; Grisariu, S; Lebel, E; Stepensky, P; Vainstein, V; Zimran, E | 1 |
| Chang, KC; Chen, JS; Cheng, CN; Chu, WY | 1 |
| An, LC; Chen, LM; Chu, XX; Feng, XY; Li, KM; Liu, XQ; Liu, YH; Ma, JJ; Sui, JR; Wang, JY; Wei, RX; Xu, JQ | 1 |
| Do, YR; Kang, HJ; Kim, HG; Kim, KH; Kim, WS; Kong, JH; Kwak, JY; Lee, JH; Lee, M; Mun, YC; Oh, SY; Park, MR; Park, SK; Park, Y; Shin, HJ; Won, JH; Yang, DH | 1 |
| An, G; Deng, S; Fu, M; Huang, W; Jiao, Y; Li, R; Liu, H; Liu, W; Lv, R; Qiu, L; Sui, W; Wang, T; Yi, S; Zhao, Y; Zou, D | 1 |
| Chen, X; Chu, J; Huang, H; Jiang, Y; Jin, Z; Li, C; Liu, S; Qian, C; Qu, C; Wu, D; Xu, T; Yang, H; Zhang, L; Zhang, X; Zhou, J; Zhu, Q | 1 |
| Bojalil-Alvarez, L; Fernández-Gutiérrez, JA; Garcia-Villasenor, E; Gomez-Almaguer, D; Gómez-Gomez, ET; Gutierrez-Aguirre, CH; Karduss-Urueta, AJ; Litzow, MR; Murrieta-Alvarez, I; Reyes-Cisneros, OA; Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ | 1 |
| Abraham, J; Agbetiafa, K; Ahle, G; Bonmati, C; Bouabdallah, K; Bouabdallah, R; Bourget, P; Casasnovas, O; Charron, C; Chauchet, A; Chinot, O; Choquet, S; Cornillon, J; Damaj, G; Delwail, V; Dorvaux, V; Fabbro, M; Fornecker, LM; Ghesquières, H; Giordan, Q; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Houot, R; Jabeur, W; Jardin, F; Le Garff-Tavernier, M; Malaise, D; Marolleau, JP; Moluçon-Chabrot, C; Morschhauser, F; Nichelli, L; Oberic, L; Peyrade, F; Plessier, A; Roland, V; Schenone, L; Schmitt, A; Soussain, C; Taillandier, L; Tanguy, ML; Tempescul, A; Thieblemont, C; Touitou, V; Ursu, R; Wantz-Mézières, S; Waultier-Rascalou, A; Willems, L | 1 |
| Feng, X; Gao, Y; Jin, M; Li, H; Li, Z; Shi, C; Song, W; Zhang, L; Zhang, M | 1 |
| Chan, EHL; Chan, JYS; Chang, EWY; Chee, YL; de Mel, S; Diong, C; Farid, M; Goh, AZK; Goh, YT; Grigoropoulos, NF; Jeyasekharan, A; Khoo, LP; Lee, J; Lee, YS; Lim, C; Lim, ST; Liu, X; Nagarajan, C; Poon, E; Poon, M; Quek, R; Somasundaram, N; Tan, D; Tang, T; Tao, M; Tay, T; Yang, VSW | 1 |
| Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L | 1 |
| André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T | 1 |
| Cui, T; Meng, G; Wang, J; Wang, Z | 1 |
| Fei, XM; Lei, F; Lu, WP; Wang, LX; Yu, XQ | 1 |
| Chang, Y; Fu, X; Li, L; Li, X; Lin, M; Nan, F; Shi, C; Sun, Z; Wang, X; Wu, X; Yan, J; Yu, H; Zhang, L; Zhang, M; Zhang, X; Zhou, Z; Zhu, L | 1 |
| Avni, B; Cohen, YI; Grisariu, S; Lebel, E; Shaulov, A; Stepensky, P; Zimran, E | 1 |
| Beleggia, F; Borkhardt, A; Burdach, S; Büttner, R; Frenzel, LP; Fritz, C; Geyer, A; Grüll, H; Hansmann, ML; Heneweer, C; Jachimowicz, RD; Klapper, W; Knittel, G; Krüger, M; Lehrmann, D; Mall, G; Merseburg, A; Ortmann, M; Paillard, A; Peifer, M; Perner, S; Persigehl, T; Reinhardt, HC; Riabinska, A; Rosenwald, A; Schmitt, A; Torgovnick, A; Utermöhlen, O; Wiederstein, JL; Wittersheim, M; Wößmann, W; Wunderlich, CM; Wunderlich, FT | 1 |
| An, HY; Choi, JY; Hong, KT; Kang, HJ; Shin, HY | 1 |
| Ballotta, L; Capria, S; Celentano, M; Ferrara, F; Marchesi, F; Mengarelli, A; Papa, E; Pedata, M; Picardi, A; Regazzo, G; Riccardi, C; Riemma, C; Terrenato, I; Trisolini, S | 1 |
| Difilippantonio, S; Huang, SN; James, A; Marzi, L; Pommier, Y; Sun, Y | 1 |
| Chen, C; Gao, Y; Guan, Z; Li, M; Liu, Y; Pan, X; Qiu, S; Wang, H; Wen, Z; Yang, S; Yuan, Y; Zeng, W; Zhang, H; Zhou, L; Zhu, Q | 1 |
| Fukuhara, N; Imaizumi, Y; Izutsu, K; Matsuda, S; Miyazaki, K; Nakazato, T; Shimada, K; Suehiro, Y; Suzuki, R; Suzumiya, J; Takahashi, T; Tomita, N; Yamaguchi, M; Yoshida, I | 1 |
| Kelsey, P; Kirkland, K; Lambert, J; Malladi, R; Morley, N; Paul, R; Pearce, R; Peniket, A; Perry, J; Snowden, JA | 1 |
| Chen, CK; Hayashi, S; Ikari, K; Kusano, J; Ogai, A; Ozawa, Y; Yamamoto, R; Yoshida, R | 1 |
| Chong, SJF; Collins, M; Davids, M; Herbaux, C; Iskandar, K; Lai, JXH; Loh, T; Low, ICC; Pervaiz, S; Qu, J; Raman, D; Valentin, R | 1 |
| Chen, J; Liu, L; Luo, X; Tang, X; Wang, L; Wang, X; Xiao, Q; Xiong, Y; Zhang, H | 1 |
| Fuji, S; Ohmoto, A | 1 |
| Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I | 1 |
| Birkmann, J; Blaudszun, AR; Bornhäuser, M; Ehninger, G; Fiedler, F; Fricke, S; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Kürzel, S; Schaefer-Eckart, K; Stahl, L | 1 |
| Ou, Y; Sun, G; Wang, H; Zhang, Z | 1 |
| Bouchaert, E; Boyé, P; Gomes, B; Hordeaux, J; Marescaux, L; Serres, F; Tierny, D | 1 |
| Eldeeb, MA; Fahlman, RP; Kramer, DA; Mercer, J; Wuest, M | 1 |
| Batlle, M; Feliu, E; Ferra, C; Garcia, O; Ibarra, G; Lopez, D; Moreno, M; Pineda, A; Ribera, JM; Sancho, JM; Sorigue, M; Tapia, G; Vives, S | 1 |
| Deng, SH; Fu, MW; Huang, WY; Li, J; Li, ZJ; Liu, H; Liu, W; Lv, R; Qiu, LG; Sui, WW; Wang, TY; Zou, DH | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Dean, R; Hamilton, B; Hill, B; Kalaycio, M; Khouri, J; Lazaryan, A; Liu, H; Majhail, N; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Beejadhursing, R; Feng, L; He, M; Jia, J; Mwamaka Sharifu, L; Wang, S; Yu, J; Zhang, J | 1 |
| Aoyama, T; Arai, H; Ikeda, T; Imataki, O; Ishide, K; Katsumata, N; Kume, T; Mori, M; Shiozaki, H | 1 |
| Birsen, R; Blanc, E; Bouscary, D; Burroni, B; Damotte, D; Deau, B; Dezamis, E; Edjlali, M; Franchi, P; Houillier, C; Kirova, Y; Le Ray, E; Legoff, M; Pallud, J; Pilorge, S; Soussain, C; Tamburini, J; Varlet, P; Vignon, M; Willems, L | 1 |
| Iseki, T; Mimura, N; Mitsukawa, S; Muto, T; Nagao, Y; Nakaseko, C; Ohwada, C; Oshima-Hasegawa, N; Ota, S; Sakaida, E; Takaishi, K; Takeda, Y; Takeuchi, M; Takiguchi, J; Tsukamoto, S | 1 |
| Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R | 1 |
| Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F | 1 |
| Bettarello, G; Costa, LJM; da Matta Abreu, M; Dos Santos, KB; Hallack Neto, AE; Mayrink, GTC; Mota, MA; Pereira, J; Ribeiro, LC | 1 |
| Kimpton, G; Maybury, B; Otton, S | 1 |
| Aboulafia, D; Ambinder, RF; Cesarman, E; Henry, D; Lee, J; Looney, D; Maldarelli, F; Mitsuyasu, R; Noy, A; Ramos, JC; Reid, EG; Sparano, J; Wachsman, W; Yahyaei, S | 1 |
| Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X | 1 |
| Hong, JY; Huh, J; Hyung, J; Kim, JH; Kim, S; Lee, SW; Park, CS; Park, JS; Ryu, JS; Suh, C; Yoon, DH | 1 |
| Castro, M; Cia, A; Duarte, P; Foncuberta, C; Gale, RP; Jaimovich, G; Lastiri, F; Longoni, H; Ostriz, MBR; Riera, L; Vitriu, A | 1 |
| Ayarza, M; Clark, SM; Hairston, A; Lentz, KL; Liu, B; Morgan, KP; Wind, LS | 1 |
| Dys, P; Jurek, T; Rorat, M; Swiatek, B | 1 |
| Bohndiek, SE; Booth, TC; Brindle, KM; Canuto, HC; Hobson, MP; Hu, DE; Kettunen, MI; Krishnan, AS; Larkin, TJ; McLachlan, C; Neves, AA | 1 |
| Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I | 1 |
| Couez, D; Delneste, Y; Donnou, S; Fremaux, I; Jarry, U; Jeannin, P; Pineau, L; Vincent, M | 1 |
| Aumont, C; Coppo, P; Fardet, L; Galicier, L; Lambotte, O; Marzac, C; Rivière, S | 1 |
| Atalla, A; Costa, LJ; dos Santos, KB; Hallack-Neto, AE; Pereira, J | 1 |
| D'Sa, S; Dorman, J; Marzolini, MA; Thomson, KJ | 1 |
| Bai, L; Greenwood, M; Kerridge, I; Ma, CK; Reid, C; Ward, C; Wong, K; Xia, W | 1 |
| Atanasova, T; Ilieva, Y; Ionkova, I; Konstantinov, S; Sasheva, P; Zaharieva, MM; Zhelezova, I | 1 |
| Abe, Y; Choi, I; Haji, S; Kiyasu, J; Ohshima, K; Suehiro, Y; Toyoda, K; Tsuda, M; Uike, N | 1 |
| Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A | 1 |
| Dehoedt, C; Jin, F; Li, F; Li, P; Rao, J; Wang, M; Yang, G; Yang, Y; Zhang, R; Zhou, Y | 1 |
| Ford, PA; Grant, SJ; Keck, G; Mick, R | 1 |
| Dietrich, S; Ho, AD; Katzke, V; Kühn, T; Kuhnt, E; Meissner, J; Pfreundschuh, M; Rixecker, T; Schmitt, T; Tichy, D; Witzens-Harig, M; Ziepert, M; Zorn, M | 1 |
| Dong, F; Ke, X; Pang, Y; Wang, J | 1 |
| Gui, L; Han, XH; He, XH; Liu, P; Qin, Y; Shi, YK; Sun, Y; Yang, S; Yao, JR; Zhang, CG; Zhang, SX; Zhao, LY; Zhou, P; Zhou, SY | 1 |
| Frey, NV; Ganetsky, A; Landsburg, DJ; Loren, AW; Luger, SM; Luskin, MR; Nasta, SD; Porter, DL; Svoboda, J | 1 |
| Duan, L; Li, J; Qiu, H; Tian, T; Wang, D; Wang, J; Zhang, Q; Zhang, X | 1 |
| Arakelyan, S; Avagyan, A; Bardakchyan, S; Danielyan, S; Hakobyan, L; Harutyunyan, L; Iskanyan, S; Safaryan, L; Sargsyan, L; Tamamyan, G; Voskanyan, A; Zohrabyan, D | 1 |
| Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
| Hotta, T; Kubo, K; Miyazaki, Y; Murayama, T; Shimazaki, R; Tamura, K; Urabe, A; Usui, N | 1 |
| Ardeshna, KM; Foley, M; Kothari, J; Lambert, J; Linch, DC; Mackenzie, S; Morris, E; Peggs, KS; Thomson, K; Virchis, AE | 1 |
| Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kako, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Medeiros, LJ; Miranda, RN; Nastoupil, LJ; Neelapu, SS; Oki, Y; Orlowski, RZ; Rodriguez, MA; Romaguera, JE; Turturro, F; Wang, M; Westin, JR | 1 |
| Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Oki, Y; Westin, JR | 1 |
| Abboud, C; Cashen, AF; Ceriotti, C; DiPersio, J; Fletcher, T; Gao, F; Ghobadi, A; Stockerl-Goldstein, K; Vij, R | 1 |
| Accordino, MK; Hershman, DL; Hillyer, GC; Neugut, AI; Vasan, S; Wright, JD | 1 |
| Borlak, J; Reymann, S | 1 |
| Cook, G; Crawley, C; Fields, P; Hickling, R; Hunter, A; Mahendra, P; Marcus, R; Peniket, A; Wilson, K | 1 |
| Brindle, KM; Day, SE; Fulton, SM; Gallagher, FA; Hu, DE; Kettunen, MI; Neves, AA; Witney, TH | 1 |
| Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P | 1 |
| Cascavilla, N; Crescimanno, A; Di Bartolomeo, P; Di Renzo, N; Lanza, F; Marcacci, G; Musso, M; Perrone, T; Pinto, A; Scalone, R | 1 |
| Bohndiek, SE; Brindle, KM; Gallagher, FA; Gisselsson, A; Hansson, G; Hu, DE; Jensen, PR; Karlsson, M; Kettunen, MI; Lerche, MH; Nelson, SK; Peitersen, T; Witney, TH; Zandt, RI | 1 |
| Biron, P; Blay, JY; Bosly, A; Casasnovas, O; Coiffier, B; Colin, P; Ferlay, C; Ghesquières, H; Haioun, C; Morel, P; Perol, D; Reman, O; Sebban, C; Tilly, H; Van den Neste, E | 1 |
| Baldini, L; Barbolini, E; Brugiatelli, M; Dell'Olio, M; Dondi, A; Federico, M; Giglio, G; Gobbi, PG; Luminari, S; Mannina, D; Merli, F; Polimeno, G; Stelitano, C | 1 |
| Avilés, A; de Jesús Nambo, M; Huerta-Guzmán, J; Neri, N | 1 |
| Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH | 1 |
| Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Copelan, O; Dean, R; Duong, H; Figueroa, P; Kalaycio, M; Koo, A; Malik, S; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Tench, S | 1 |
| Andresen, S; Avalos, B; Bolwell, BJ; Copelan, E; Dean, R; Devine, S; Elder, P; Kalaycio, M; Mahindra, A; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Tench, S | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Balzer, RJ; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Khouri, I; McMannis, J; Popat, U; Qazilbash, M; Rhodes, B; Smith, V; Thompson, R; Walters, K | 1 |
| Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C | 1 |
| Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T | 1 |
| Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
| Abramson, JS; Armand, P; Brown, JR; Chen, YB; Feng, Y; Fisher, DC; Freedman, AS; Jacobsen, ED; LaCasce, AS; Lane, AA; McAfee, SL; Neuberg, DS; Spitzer, TR | 1 |
| Madtes, DK; Till, BG | 1 |
| Behler, CM; Cha, S; Damon, LE; Hwang, J; Issa, S; McDermott, M; O'Brien, J; Rubenstein, JL; Shuman, MA; Treseler, P; Valles, F; Wieduwilt, MJ | 1 |
| Bishop, MR; Bryant, K; Dean, RM; Dunleavy, K; Fowler, DH; Fry, TJ; Gress, RE; Hakim, F; Hughes, TE; Odom, J; Pavletic, SZ; Salit, RB; Steinberg, SM; Wilson, WH | 1 |
| Berger, SA; Li, H; Martin, A; Nepal, RM | 1 |
| Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H | 1 |
| Degnan, AJ; Levy, LM | 1 |
| Coleman, M; Elstrom, RL; Leonard, JP; Martin, P; Ruan, G | 1 |
| Anderson, DJ; Belmont, LD; Bouillet, P; Campbell, KJ; Cory, S; Fairlie, WD; Glaser, SP; Huang, DC; Khaw, SL; Lee, EF; Ludlam, MJ; Mérino, D; Phipson, B; Robati, M; Roberts, AW; Vandenberg, CJ; Wong, C; Yue, P | 1 |
| Happo, L; Phipson, B; Scott, CL; Smyth, GK; Strasser, A | 1 |
| Cavallini, S; Mariani, L; Rainaldi, G; Rizzo, M; Simili, M | 1 |
| Boyd, TE; Budde, LE; Chen, TL; Frayo, SL; Gooley, TA; Gopal, AK; Kammerer, BE; Knudsen, NL; Oliveira, GR; Pagel, JM; Press, OW; Roden, JE; Shustov, AR; Warr, TA; Zhang, MM | 1 |
| Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E | 1 |
| Crump, M; Keating, A; Mollee, P; Nagy, T; Pereira, D; Saragosa, R; Song, K | 1 |
| Grigg, AP; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J | 1 |
| D'Orazio, A; Gibson, AD | 1 |
| Emmanouilides, C; Grody, W; Lill, M; Rosen, P; Rosenfelt, F; Telatar, M; Territo, M | 1 |
| Staudt, LM; Wilson, WH | 1 |
| Ben-Schachar, M; Epelbaum, R; Haim, N; Kuten, A; Stein, ME; Zaidan, J | 1 |
| Bökönyi, G; Horváth, A; Kéri, G; Szende, B | 1 |
| Aoki, Y; Kataoka, C; Nomiyama, K; Shibuya, T | 1 |
| Briggs, A; Chow, HH; Dorr, RT; Kintzel, P; List, A; Meyers, R | 1 |
| Doolittle, ND; Kraemer, DF; Lacy, C; Neutwelt, EA; Siegal, T; Tyson, RM | 1 |
| Chang, MC; Chao, TY; Chen, LT; Chen, PJ; Cheng, AL; Hsiung, CA; Hsu, CH; Kao, WY; Su, IJ; Tien, HF; Tsao, CJ; Uen, WC; Whang-Peng, J | 1 |
| Aylott, M; Burman, M; Harvey, J; Lynch, A; Nicholas, E; Rees, R; Siddiqui, A; Walker, S | 1 |
| Kagami, Y; Miura, K; Morishima, Y; Ogura, M; Suzuki, R; Taji, H; Takeuchi, T | 1 |
| Duncan, A; Lachance, S; Mangel, J | 1 |
| Shacter, E; Zhang, B; Zhang, Y | 2 |
| Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL | 1 |
| Fil'chenkov, AA; Nesina, IP; Smirnova, IA; Zavelevich, MP | 1 |
| Hanioka, K; Maeda, A; Matsushita, A; Nagai, K; Sugimoto, N; Takahashi, T; Watanabe, N | 1 |
| Caballero, MD; del Cañizo, MC; García-Sanz, R; López, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Aibe, H; Asayama, Y; Honda, H; Irie, H; Kakihara, D; Matake, K; Nakamura, K; Nakayama, T; Nishie, A; Ohga, S; Tajima, T; Yamamoto, N; Yoshimitsu, K | 1 |
| Ballestrero, A; Boy, D; Brossart, P; Garuti, A; Mela, GS; Nencioni, A; Patrone, F; Rocco, I; Van Parijs, L; Wesselborg, S | 1 |
| Avalos, B; Bechtel, T; Copelan, E; Elder, P; Ezzone, S; Farag, S; Hoshaw-Woodard, S; Lemeshow, S; Lin, T; Marcucci, G; Penza, S; Scholl, MD | 1 |
| Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH | 1 |
| Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M | 1 |
| Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S | 1 |
| Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA | 1 |
| Ikarashi, Y; Imai, C; Kakihara, T; Tanaka, A; Uchiyama, M; Watanabe, A | 1 |
| Baldinger, C; Fridrik, MA; Greil, R; Hausmaninger, H; Klocker, J; Krieger, O; Linkesch, W; Oberaigner, W; Pont, J | 1 |
| Aydin, F; Bektas, O; Kavgaci, H; Ozdemir, F; Yavuz, AA; Yavuz, MN; Yilmaz, M | 1 |
| Berg, SL; Bessmertny, O; Cairo, MS; Davenport, V; Goldman, SC; Kreissman, SG; Laver, J; Reaman, GH; Secola, R; Shen, V; van de Ven, C | 1 |
| Abdi, E; Biagi, JJ; Dale, B; Falkson, C; Herbert, KE; Januszewicz, H; Leahy, M; Matthews, JP; Prince, HM; Richards, K; Seymour, JF; Smith, C; Wolf, M | 1 |
| Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Boxer, LM; Wang, J | 1 |
| Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH | 1 |
| Hondoh, H; Morii, K; Onda, K; Shinbo, Y; Takahashi, H; Takeuchi, S; Tamura, T; Tanaka, R; Yamanaka, R | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Hatae, M; Hirabayashi, K; Noda, K; Ogawa, M; Takaku, F; Yakushiji, M | 1 |
| Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M | 1 |
| Chuttani, K; Harivardhan Reddy, L; Mishra, AK; Murthy, RS; Sharma, RK | 1 |
| Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A | 1 |
| Nishida, T; Oguma, T; Ono, T; Sato, M; Tadakuma, T; Tsujimoto, K | 1 |
| Brindle, KM; Hu, DE; Kettunen, MI; Schmitz, JE | 1 |
| Dagher, MC; Shacter, E; Zhang, B; Zhang, Y | 1 |
| Cai, Z; Huang, H; Li, L; Lin, MF; Luo, Y; Meng, XJ; Xie, WZ | 1 |
| Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I | 1 |
| Takahashi, H; Tanaka, R | 1 |
| Cho, JH; Kim, HS; Ko, YH; Park, CS | 1 |
| Earnshaw, WC; Kaufmann, SH; Loegering, DA; Ruchaud, S | 1 |
| Berdel, WE; Dorken, B; Glass, B; Kloess, M; Kneba, M; Loeffler, M; Metzner, B; Pfreundschuh, M; Reiser, M; Schmitz, N; Trumper, L | 1 |
| Abali, H; Dizdar, O; Erdem, I; Eren, OO; Erman, M; Karadağ, O; Türker, A; Uluç, K; Yilmaz, A | 1 |
| Horiike, S; Kanbayashi, Y; Matsumoto, Y; Mukoyama, N; Nishida, K; Nomura, K; Shimizu, D; Taniwaki, M | 1 |
| Akbulut, T; Boulares, H; Kandan, S; Oumouna, M; Yakovlev, A; Zoltoski, A | 1 |
| Aoki, S; Hirano, M; Miura, I; Niitsu, N; Okamoto, M; Okumura, H; Yoshino, T | 1 |
| Beguin, Y; Fillet, G; Frère, P; Ngirabacu, MC; Vanstraelen, G; Willems, E | 1 |
| Murthy, RR; Reddy, LH; Sharma, RK | 1 |
| Adhikari, JS; Dwarakanath, BS; Murthy, RR; Reddy, LH; Sharma, RK | 1 |
| Björkholm, M; Celsing, F; Johansson, E | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
| Blechschmidt, M; Bornhäuser, M; Ehninger, G; Hänel, M; Hölig, K; Kroschinsky, F; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Poppe-Thiede, K; Schaich, M | 1 |
| Bay, JO; Berthou, C; Bertrand, P; Brion, A; Camilleri-Broët, S; Colombat, P; Delepine, R; Delwail, V; Desablens, B; Lamy, T; Lemevel, A; Linassier, C; Rachieru, P | 1 |
| Kansu, E; Kars, A; Koc, Y; Oyan, B; Ozdemir, E; Tekuzman, G; Turker, A | 1 |
| Arellano, M; Flowers, C; Heffner, LT; Hutcherson, D; Jo Lechowicz, M; Langston, A; Lonial, S; Waller, EK; Winton, E | 1 |
| Boudrias, M; Fortin, D; Garant, MP; Gendron, C | 1 |
| Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A | 1 |
| Arber, C; Bucher, C; Buser, AS; Ghielmini, M; Gratwohl, A; Halter, J; Heim, D; Lohri, A; Meyer-Monard, S; Passweg, JR; Stern, M; Stussi, G; Tichelli, A | 1 |
| Homma, J; Hondoh, H; Morii, K; Onda, K; Sano, M; Shinbo, Y; Takahashi, H; Tamura, T; Tanaka, R; Tsuchiya, N; Yajima, N; Yamanaka, R | 1 |
| Ference, SJ; Galor, A; Lee, MS; Peereboom, DM; Perez, VL; Singh, AD; Stevens, GH | 1 |
| Hardan, I; Shimoni, A | 1 |
| Avola, G; Battiato, K; Camuglia, MG; Coppoletta, S; Giustolisi, R; Leotta, S; Mauro, E; Mercurio, S; Milone, G; Murgano, P; Pinto, V; Poidomani, M; Strano, A | 1 |
| Imataki, O; Kawakami, K; Tamai, Y | 1 |
| Aoyama, T; Imataki, O; Kawakami, K; Tamai, Y | 1 |
| Ardenkjaer-Larsen, JH; Brindle, KM; Day, SE; Gallagher, FA; Golman, K; Hu, DE; Kettunen, MI; Lerche, M; Wolber, J | 1 |
| Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S | 1 |
| Goldstein, DA; Tessler, HH | 1 |
| Brindle, KM; Davletov, B; de Backer, MM; Hu, DE; Kettunen, MI; Krishnan, AS; Neves, AA | 1 |
| Coleman, M; Elstrom, R; Furman, R; George, P; Kaufman, TP; Leonard, JP; Martin, P; Niesvizky, R; Ruan, J | 1 |
| Grifols, JR; Juncà, J; Morgades, M; Ribera, JM; Sancho, JM; Vives, S | 1 |
| Bishton, MJ; Fox, CP; Haynes, AP; McMillan, AK; Russell, NH | 1 |
| Homma, J; Hondoh, H; Kakuma, T; Morii, K; Sano, M; Shinbo, Y; Takahashi, H; Tamura, T; Tanaka, R; Tsuchiya, N; Yajima, N; Yamanaka, R | 1 |
| Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ | 1 |
| Barlogie, B; Cabanillas, F; Freireich, EJ; Keating, M | 1 |
| Kennedy, BJ; Raghavan, D; Vogelzang, NJ | 1 |
| Heinz, R; Stacher, A | 1 |
| Płuzańska, A; Robak, T | 1 |
| Dicke, KA; Hagemeister, FJ; Jagannath, S; Kanojia, M; McLaughlin, P; Spitzer, G; Tannir, NM; Vellekoop, L; Zander, AR | 1 |
| Hattori, K; Ito, K; Kobayashi, S; Nakamura, S; Nakanishi, J; Ohtake, S; Yoshida, T | 1 |
| Adachi, K; Horikoshi, N; Ingaki, J; Inoue, K; Mukaiyama, T; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H | 1 |
| Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SM; Longo, DL; Wesley, R; Young, RC | 1 |
| Berg, C; Bottino, G; Chabner, B; Doyle, LA | 1 |
| Bremer, K; Niederle, N; Scheulen, ME; Seeber, S | 1 |
| Fukuoka, M; Kimura, I; Kuraishi, Y; Ogawa, M; Ohnoshi, T; Ota, K; Oyama, A; Sanpi, K; Takada, M; Yoshida, S | 1 |
| Hayashi, K; Nishihara, R; Onoshi, T; Toyota, K; Ueoka, H | 1 |
| Ferrazzi, E; Fiorentino, MV; Fosser, VP; Pappagallo, GL; Salvagno, L; Segati, R; Sileni, VC | 1 |
| Brennan, MF; Fisher, RI; Popp, MB; Simon, RM | 1 |
| Jungi, WF; Kroner, T; Obrecht, JP | 1 |
| Nagel, GA; Scherpe, A; von Heyden, HW | 1 |
| Arnold, AM; Whitehouse, JM | 1 |
| Barrett, A; McElwain, TJ; Peckham, MJ; Taylor, RE | 1 |
| Bodey, GP; Cabanillas, F; Freireich, EJ; Hagemeister, FB | 1 |
| Dicato, M | 1 |
| Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Chang, J; Crowther, D; Morgenstern, GR; Pettengell, R; Radford, JA; Rowlands, M; Scarffe, JH; Testa, NG; Woll, PJ; Young, R | 1 |
| Chan, T; Cooper, I; Januszewicz, E; Juneja, S; Wolf, M | 1 |
| Cerny, T; Fey, M; Honegger, H; Jacky, E; Jost, LM; Pichert, G; Platzer, E; Stahel, RA; Tobler, A | 1 |
| Hirano, M | 1 |
| Ariyama, Y; Fujii, H; Nakagawa, H; Sonoda, Y | 1 |
| Fuchsberger, P; Lakota, J | 1 |
| Fehr, J; Rüegg, R; Schleiffenbaum, B; Zimmermann, D | 1 |
| Ben-Shahar, M; Epelbaum, R; Haim, N | 1 |
| Ichikawa, Y; Kawada, H; Mukaiyama, T; Ogawa, Y; Watanabe, S | 1 |
| Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D | 1 |
| Alvarez, M; Dickstein, B; Kang, YK; Lee, JS; Meadows, B; Otsuki, T; Regis, J; Robey, R; Stetler-Stevenson, M; Zhan, Z | 1 |
| Balis, FM; Bates, SE; Bryant, G; Chabner, BA; Jamis-Dow, C; Klecker, RW; Kohler, DR; Steinberg, SM; Wilson, WH; Wittes, RE | 1 |
| Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z | 1 |
| Fujii, H; Kuzuyama, Y; Maekawa, T; Nakagawa, H; Sonoda, Y | 1 |
| Watkins, SM | 1 |
| Boccadoro, M; Bondesan, P; Bregni, M; Caracciolo, D; Frieri, R; Gianni, AM; Omedé, P; Pileri, A; Siena, S; Tarella, C | 1 |
| Bertini, M | 1 |
| Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M | 1 |
| Collins, R; Fay, J; Herzig, G; Pineiro, L | 1 |
| Amylon, MD; Blume, KG; Chao, NJ; Kusnierz-Glaz, C; Long, GD; Negrin, RS | 1 |
| Cavalli, F; Cerny, T; De Fusco, M; De Jong, J; Gentili, D; McDaniel, C; Pagani, O; Prins, C; Sessa, C; Zucchetti, M | 1 |
| Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E | 1 |
| Daly, MB; Giguere, JK; Harden, EA; Harman, GH; Johnson, DB; Johnson, RA; Leff, RS; Mercier, RJ; Messerschmidt, GL; Snyder, MJ | 1 |
| Blaschke, TF; Blume, KG; Chao, NJ; Horning, SJ; Kastrissios, H; Long, GD; Negrin, RS; Wong, RM | 1 |
| Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH | 1 |
| Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A | 1 |
| Hashimoto, S; Hasuike, T; Hirai, M; Hirai, N; Kou, KR; Ohta, K; Ohta, T; Takekawa, K; Tanaka, K; Yamane, T | 1 |
| Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Okawa, K; Oku, N; Shimazaki, C; Yamagata, N | 1 |
| Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L | 1 |
| Barbot, C; Jazwiec, B; Mahon, FX; Reiffers, J; Rice, A; Vanès, I | 1 |
| Ashby, J; Callander, RD; Clive, D; Glover, P; Krehl, R; Poorman-Allen, P; Tinwell, H | 1 |
| Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W | 1 |
| Aisner, J; Belani, CP; Doyle, LA | 1 |
| Muggia, FM | 1 |
| Joel, SP; Shah, R; Slevin, ML | 1 |
| Cabanillas, F; Rodriguez, MA | 1 |
| Andersson, BS; Dimopoulos, M; Gajewski, J; Giralt, SA; Khouri, I; LeMaistre, CF; Mehra, R; Przepiorka, D; Van Besien, K; Vriesendorp, HM | 1 |
| Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Rubenstein, E; Swan, F; Tucker, S; Velasquez, WS | 1 |
| Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D | 1 |
| Anasetti, C; Appelbaum, FR; Bensinger, W; Bianco, J; Clift, R; Martin, P; Petersen, FB; Press, O; Singer, J; Weaver, CH | 1 |
| Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, H; Shina, DC; Topolsky, D | 1 |
| Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S | 1 |
| Denzlinger, C; Gerhartz, HH; Walther, J; Wilmanns, W | 1 |
| Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K | 1 |
| Johnson, PW; Lister, TA; McCallum, P; Norton, AJ; Rohatiner, AZ; Sweetenham, JW | 1 |
| Carlson, K; Hagberg, H; Oberg, G; Simonsson, B; Smedmyr, B | 1 |
| Smith, RJ; Sweetenham, JW | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 1 |
| Goldstone, AH; Linch, DC; Mills, W; Strang, J | 1 |
| Brummett, RE; Dahlborg, SA; Dana, BW; Henner, WD; Neuwelt, EA; Roman-Goldstein, S; Tableman, M; Williams, PC | 1 |
| Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R | 1 |
| Fujioka, S; Kato, K; Tomono, H | 1 |
| Xu, J; Zhang, X; Zhu, H | 1 |
| Avilés, A; Delgado, S; Díaz-Maqueo, JC; García, EL; Guzmán, R; Nambo, MJ | 1 |
| Ager, S; Baglin, TP; Bass, G; Mahendra, P; Marcus, RE; Richards, EM | 1 |
| Akutsu, M; Kano, Y; Suzuki, K; Tsunoda, S | 1 |
| Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Osby, E; Peterson, C; Sirzea, F; Söderhäll, S; Zhou, R | 1 |
| Appelbaum, FR; Bensinger, WI; Brunvand, MW; Buckner, CD; Chauncey, T; Clift, RA; Demirer, T; Dorn, R; Fefer, A; Gooley, TA; Holmberg, LA; Lilleby, K; Martin, PL; Maziarz, RT; McSweeney, PA; Montgomery, P; Press, OW; Rowley, SD; Sanders, JE; Schiffman, K; Soll, E; Storb, R; Weaver, CH; Weiden, PL; Zuckerman, N | 1 |
| Fielding, AK; Goldstone, AH; Jamieson, E; Linch, DC; Sullivan, AM; Watts, MJ | 1 |
| Kizaki, H; Onishi, Y | 2 |
| Hagel, E; Hering, M; Krieger, G; Zwicker, C | 1 |
| Masaoka, T | 1 |
| Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E | 1 |
| Bates, SE; Dickstein, B; Fojo, AT; Gamelin, E; Regis, J; Sandor, VA; Wilson, W; Zhan, Z | 1 |
| Asaka, M; Hashino, S; Imamura, M; Kasai, M; Kobayashi, S; Sakurada, K; Tanaka, J | 1 |
| Anderson, S; Haynes, AP; McQuaker, IG; Russell, NH; Stainer, C | 1 |
| Fujita, M; Murata, M; Nagai, M; Ohmori, M; Takahara, J | 1 |
| Brunet, S; Cancelas, JA; García, J; Madoz, P; Martínez, C; Martino, R; Sureda, A | 1 |
| Joshi, B; Li, L; Tang, DG; Zhu, Z | 1 |
| Okamoto, M | 1 |
| Constine, LS; Hicks, DG; O'Keefe, R; Packman, CH; Rapoport, AP; Rosier, RN; Rowe, JM; Rubin, SJ | 1 |
| Bairey, O; Blickstein, D; Epstein, O; Gabbay, U; Lahav, J; Prokocimer, M; Shaklai, M; Stark, P | 1 |
| Colomer, R; Gómez, H | 1 |
| Buckner, CD; Schwartzberg, L; Upton, S; Walker, C; Weaver, CH; Zhen, B | 1 |
| Fehse, N; Gutensohn, K; Hassan, HT; Kröger, N; Krüger, W; Lölliger, C; Zander, AR; Zeller, W | 1 |
| Bushell, M; Clemens, MJ; Morley, SJ | 1 |
| Cavalli, F; Ghielmini, M; Sanna, P; Van den Bosch, S | 1 |
| Korístek, Z; Mayer, J; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Chowhan, N; Davis, R; Hentschel, P; Iliya, A; Madajewicz, S; Manzione, J; Meek, A; Roche, P; Roque, C; Shady, M; Tfayli, A | 1 |
| Hatzl-Griesenhofer, M; Huber, H; Maschek, W; Pichler, R; Wahl, G; Wimmer, G | 1 |
| Chemnitz, J; Diehl, V; Draube, A; Engert, A; Josting, A; Mapara, MY; Reiser, M; Scheid, C; Söhngen, D; Tesch, H; Wolf, J | 1 |
| Arita, K; Harada, K; Ide, T; Kurisu, K; Sadatomo, T; Tahara, E; Tahara, H; Uozumi, T | 1 |
| Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A | 1 |
| Hunter, N; Meyn, RE; Mirkovic, N; Story, MD | 1 |
| Devereux, S; Goldstone, AH; Ings, SJ; Leverett, D; Linch, DC; MacMillan, A; Watts, MJ | 1 |
| Arber, DA; Bhatia, R; Bhatia, S; Forman, SJ; Fung, H; Kashyap, A; Krishnan, A; Molina, A; Nademanee, A; Niland, JC; O'Donnell, MR; Parker, PA; Slovak, ML; Sniecinski, I; Snyder, DS; Spielberger, R; Stein, A | 1 |
| Greco, FA | 1 |
| Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J | 1 |
| Heinz, R; Karlic, H; Mühlberger, H; Pavlova, B; Pfeilstöcker, M; Pittermann, E; Salamon, J; Strobl, H | 1 |
| Altés, A; Briones, J; Brunet, S; Cabezudo, E; López, R; Madoz, P; Martinez, C; Martino, R; Muñoz, L; Perea, G; Salar, A; Santamaría, A; Sierra, J; Sureda, A | 1 |
| Brugarolas, A; Calvo, JP; Gonzalez Manzano, R; Jimenez, MM; Lopez-Picazo, JM; Ordoñez Tres, JM | 1 |
| Chemnitz, J; Diehl, V; Draube, A; Engert, A; Fuchs, M; Josting, A; Reiser, M; Scheid, C; Schultz, A; Söhngen, D; Winter, S | 1 |
| Hatano, H; Hatano, N; Kajita, Y; Kinoshita, T; Takasu, S; Usui, T; Wakabayashi, T; Yoshida, J | 1 |
| Klener, P; Procházka, B; Slabý, J; Trnený, M | 1 |
| Guinness, ME; Kenney, JL; Lacy, J; Reiss, M | 1 |
| Beauchemin, M; Bertrand, R; Droin, N; Solary, E | 1 |
| Chan, JK; Cheung, MM; So, JC; Wong, KF | 1 |
| Lim, MS; Lim, S; Lin, Z; Sapp, M; Viani, MA | 1 |
| Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Rusten, LS | 1 |
| Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K | 1 |
| Cernilová, I; Doubek, M; Klabusay, M; Korístek, Z; Mayer, J; Navrátil, M; Petráková, K; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Browne, PV; Daly, PA; Duggan, C; Enright, H; Gardiner, N; Kennedy, MJ; McCann, SR; O'Connell, N | 1 |
| Beyer, J; Huhn, D; Kingreen, D; Kleiner, S; Reif, S; Siegert, W | 1 |
| Brand, K; Buttgereit, P; Ebert, O; Märten, A; Renoth, S; Schakowski, F; Schmidt-Wolf, IG; Schöttker, B; Schroers, R; Ziske, C | 1 |
| Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ | 1 |
| Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ | 1 |
| Grimm, J; Jaehde, U; Kingreen, D; Kloft, C; Reif, S; Schunack, W; Siegert, W | 1 |
| Larsson, R; Liminga, G; Martinsson, P; Nygren, P | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Alessandrino, EP; Arcaini, L; Astori, C; Bernasconi, P; Brusamolino, E; Cairoli, R; Calatroni, S; Colombo, AA; Gargantini, L; Iacona, I; Lazzarino, M; Morra, E; Orlandi, E; Pagnucco, G; Regazzi, MB | 1 |
| Fukuhara, S; Kanazawa, S; Kuwana, M; Nomura, S; Yamaguchi, K; Yoshimura, C | 1 |
| Arai, T; Hanada, R; Ida, K; Inatomi, J; Kawaguchi, H; Kikuchi, A; Kishimoto, H; Oh-Ishi, T; Taketani, T; Yamamoto, K | 1 |
| Aggarwal, S; Arora, A; Bhalla, S; Murthy, SA; Singh, B; Vohra, R | 1 |
| Hagemeister, FB | 1 |
| Campbell, AK; Chin, SF; Davies, S; Errington, RJ; Smith, PJ; Wiltshire, M | 1 |
| Bunn, PA; Ihde, DC; Radice, PA | 1 |
| Henney, JE; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
| Crooke, ST; Issell, BF | 1 |
| Arnold, AM | 1 |
| Al-Sarraf, M; Cecil, JW; Coltman, CA; Groppe, CW; Quagliana, JM; Thigpen, T | 1 |
| Barlogie, B; Drewinko, B | 1 |
| Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Lombardi, F; Magni, M; Pileri, A; Siena, S; Tarella, C | 1 |
| Chabner, BA; Duffey, PL; Longo, DL; Urba, WJ; Wilson, WH; Wittes, R | 1 |
| Hotta, T; Kiya, K; Kurisu, K; Mikami, T; Ogasawara, H; Sugiyama, K; Uozumi, T | 1 |
| Ezaki, K; Hirano, M; Maruyama, F; Okamoto, M | 1 |
| Ashihara, E; Fujita, N; Goto, H; Inaba, T; Ito, K; Murakami, S; Okawa, K; Oku, N; Shimazaki, C; Tsuji, H | 1 |
| Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D | 1 |
| Bryant, G; Carter, C; Cottler-Fox, M; Cowan, KH; Goldspiel, B; Jain, V; Longo, DL; Steinberg, SM; Wilson, WH; Wittes, RE | 1 |
| Fay, JW; Harden, EA; Herzig, GP; Herzig, RH; Heye, MM; Meagher, RC; Montes, VM; Stevens, DA | 1 |
| Blume, KG; Forman, SJ | 1 |
| Janmohammed, RM; Leyland, MJ; Long, SG; Macdonald, DF; Milligan, DW; Smith, AG | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, RA; Deeg, HJ; Petersen, FB; Sanders, JE; Storb, R; Sullivan, KM; Witherspoon, RP | 1 |
| Rybka, WB | 1 |
| Chang, SC; Hsu, JR; Perng, RP | 1 |
| Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S | 1 |
| Di Noto, R; Fabbiano, F; Gentile, S; Guarnaccia, C; Indovina, A; Majolino, I; Patti, C; Santoro, A; Scimè, R; Vasta, S | 1 |
| Maca, RD | 1 |
| Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ | 1 |
| Cabanillas, F | 2 |
| Airo, I; Helve, O; Hiltunen, KM; Mattila, J | 1 |
| Brashear, T; Fay, J; Miller, G; Stone, M | 1 |
| Connors, JM; Klimo, P; O'Reilly, SE | 1 |
| Brincker, H; Mirza, MR | 1 |
| Frazier, SR; Greco, FA; Hainsworth, JD; Johnson, DH | 1 |
| Creger, RJ; Fox, RM; Lazarus, HM | 1 |
| Akiyama, Y; Ito, M; Kamiya, H; Kawa, K; Mikawa, H; Miyazaki, S; Sakurai, M; Tujino, G; Ueda, K | 1 |
| Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE | 1 |
| Pawlicki, M; Rachtan, J; Sliz, E | 1 |
| Burns, LJ; Fyfe, MA; Ginder, GD; Gingrich, RD; Wen, BC | 1 |
| Bolwell, BJ; Brown, RA; Frei-Lahr, D; Hande, KR; Harden, EA; Herzig, GP; Herzig, RH; Lowder, JN; Pineiro, L; Wolff, SN | 1 |
| Gulati, SC; Lemoli, RM | 1 |
| Bron, D; Stryckmans, P; Vandenheule, B | 1 |
| Colvin, OM; Santos, GW | 1 |
| Gaynor, E; Ultmann, JE; Watson, S; Williams, SF | 1 |
| DeVita, VT | 1 |
| Daly, PA; Finn, T; Lawlor, E; O'Briain, DS; O'Brien, AA; Rogers, FM; Ward, R | 1 |
| Atzpodien, J; Clarkson, BD; Colvin, OM; Gulati, SC; Jain, K; Langleben, A; Ng, RP; Shimazaki, C; Yopp, J | 1 |
| Douay, L | 1 |
| Goto, S; Hotta, T; Ichikawa, A; Inoue, C; Murate, T; Nagura, E; Ninomiya, N; Ohnishi, K; Tsushita, K; Utsumi, M | 1 |
| Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M | 1 |
| Hamada, H; Ishida, Y; Minato, K; Ohtsu, T; Shimoyama, M; Sugimoto, Y; Tobinai, K; Tsuruo, T | 1 |
| DeVita, VT; Fisher, RI; Longo, D; Young, RC | 1 |
| Jones, RJ; Santos, GW | 1 |
| Cassileth, PA; Gale, RP; Stadtmauer, EA | 1 |
| DeVita, VT; Duffey, PL; Fisher, RI; Gilliom, M; Glatstein, E; Hubbard, SM; Ihde, DC; Jaffe, ES; Longo, DL; Young, RC | 1 |
| Alonso, MT; Leyland-Jones, B; Marsoni, S; O'Dwyer, PJ; Wittes, RE | 1 |
| Kimura, K; Niitani, H; Yamada, K | 1 |
| Cummings, J; Cunningham, D; Forrest, GJ; McTaggart, L; Soukop, M; Stuart, JF | 1 |
| Cabanillas, F; Hagemeister, FB; Jagannath, S; McLaughlin, P; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS | 1 |
| Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ | 1 |
| Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ | 1 |
| Pawlicki, M; Sliz, E; Zuchowska-Vogelgesang, B | 1 |
| Greist, A; Hoffman, R; Kubilis, PS; Loehrer, PJ; Nichols, CR | 1 |
| Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Kohsaki, M; Masaoka, T; Nagai, K; Shibata, H; Tagawa, S; Tsubaki, K | 1 |
| Appelbaum, FR; Buckner, CD | 1 |
| Lampkin, BC; Wong, KY | 1 |
| Andreeff, M; Ciobanu, N; Paietta, E; Papenhausen, P; Wiernik, PH | 1 |
| Grosh, WW; Hande, KR; Prater, K; Wolff, SN | 1 |
| Carcassonne, Y; Finaud, M; Gastaut, JA; Horchowski, N; Lejeune, C; Sainty, D; Sebahoun, G; Tubiana, N | 1 |
| Háber, J; Klener, P | 1 |
| Fujii, H; Iwai, M; Kashiwadani, M; Maekawa, T; Miyoshi, M; Suyama, Y; Urata, Y | 1 |
| Castro-Malaspina, H; Gulati, SC; Kushner, BH; Kwon, JH | 1 |
| Atkins, C; Coonley, CJ; Danieu, L; Warrell, RP | 1 |
| Cabanillas, F; Fuller, L; Hagemeister, FB; McLaughlin, P; Riggs, S; Smith, T; Velasquez, WS | 1 |
| Abe, T; Kariyone, S; Maekawa, I; Maekawa, T; Miura, A; Miura, Y; Moriyama, Y; Shibata, A; Wakui, A; Yoshida, Y | 1 |
| Ogawa, M | 1 |
| Crowther, D; Gasser, AB; Scarffe, JH; Steward, WP; Wagstaff, J | 1 |
| Dent, DM; Hayes, M; Jacobs, P; King, HS | 1 |
| Cavallin-Ståhl, E; Hagberg, H; Lind, J | 1 |
| Kimura, K; Yamada, K; Yoshida, T | 1 |
| Arakawa, S; Esumi, N; Imashuku, S; Todo, S | 1 |
| Ito, K; Kobayashi, K; Matsuda, T; Nakagoshi, T; Nakamura, E; Nakamura, S; Nakanishi, J; Natori, K; Ohtake, S; Yoshida, T | 1 |
| Aisner, J; Egorin, MJ; Jones, JM; Olman, EA | 1 |
| Hancock, BW | 1 |
| Cavalli, F | 1 |
| Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Kohsaki, M; Konishi, I; Masaoka, T; Nagai, K; Shibata, H; Tsubaki, K | 1 |
| Judson, IR; Wiltshaw, E | 1 |
| Hiraki, S; Kimura, I; Miyamoto, H; Murashima, M; Ohnoshi, T; Toyata, K; Ueno, K; Ueoka, H; Yamane, T | 1 |
27 review(s) available for etoposide and Lymphoma
| Article | Year |
|---|---|
Focus on lymphomas.
Topics: Alemtuzumab; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Etoposide; Gene Expression; Humans; Interleukin-2; Lymphoma; Prednisone; Risk Factors; Rituximab; Survival; Vaccines; Vincristine | 2002 |
[Chemotherapy for brain tumor].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Delivery Systems; Etoposide; Humans; Lymphoma; Medulloblastoma; Methotrexate; Neoplasms, Germ Cell and Embryonal; Nimustine; Oligodendroglioma; Platinum Compounds; Randomized Controlled Trials as Topic; Vincristine | 2005 |
The hematologic malignancies. Leukemia, lymphoma, and myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Interferons; Leukemia; Lymphoma; Mechlorethamine; Multiple Myeloma; Prednisone; Procarbazine; Prognosis; Translocation, Genetic; Vincristine | 1984 |
[Malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Vincristine | 1994 |
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Etoposide: current status and future perspectives in the management of malignant neoplasms.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Germinoma; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Sarcoma, Kaposi; Stomach Neoplasms | 1994 |
Teniposide: overview of its therapeutic potential in adult cancers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Etoposide; Female; Genital Neoplasms, Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma, Kaposi; Teniposide | 1994 |
Etoposide dosage and pharmacodynamics.
Topics: Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Kidney Function Tests; Liver; Liver Function Tests; Lung Neoplasms; Lymphoma | 1994 |
[Etoposide 21 therapy for malignant lymphoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Palliative Care | 1996 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Palliative Care; Prednimustine; Prednisolone; Prednisone; Prognosis; Vincristine | 1998 |
Oral etoposide in lymphoma.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Etoposide; Humans; Lymphoma | 1999 |
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymphoma; Mesna; Methylprednisolone; Mitoxantrone | 2001 |
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma; Middle Aged; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Vincristine | 2002 |
VM 26 and VP 16-213: a comparative analysis.
Topics: Animals; Brain Neoplasms; Drug Evaluation; Etoposide; Humans; Kinetics; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms, Experimental; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1977 |
Etoposide (VP-16-213).
Topics: Adult; Animals; Bone Marrow; Cell Cycle; Child; Digestive System; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Neoplasms; Neoplasms, Experimental; Podophyllotoxin; Rats | 1979 |
Podophyllotoxin derivative VP 16-213.
Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma | 1979 |
Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Lymphoma; Methotrexate; National Institutes of Health (U.S.); Prednisone; United States; Vincristine | 1992 |
High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Etoposide; Humans; Leukemia; Lymphoma; Multiple Myeloma; Whole-Body Irradiation | 1992 |
The evolving role of etoposide in the management of lymphomas and Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin | 1991 |
[Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Vincristine | 1985 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lysophosphatidylcholines; Methylprednisolone; Neoplasms, Experimental; Phospholipid Ethers; Pyrimidinones; Transplantation, Autologous; Transplantation, Isogeneic | 1986 |
Pharmacological bone marrow purging with drugs other than cyclophosphamide derivatives.
Topics: Animals; Antineoplastic Agents; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Etoposide; Humans; Leukemia; Lymphoma; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Preoperative Care | 1989 |
Experience with ifosfamide combinations in malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexate; Mitoguazone | 1989 |
Etoposide in leukemia, lymphoma and bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Etoposide; Humans; Leukemia; Lymphoma | 1989 |
Etoposide (VP-16-213). Current status of an active anticancer drug.
Topics: Animals; Carcinoma, Small Cell; Clinical Trials as Topic; DNA; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Podophyllotoxin; Testicular Neoplasms; Tissue Distribution | 1985 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Indications for and benefits of intensive therapies in treatment of childhood cancers.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Methotrexate; Neoplasms; Osteosarcoma; Risk; Sarcoma, Ewing | 1986 |
108 trial(s) available for etoposide and Lymphoma
| Article | Year |
|---|---|
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul
Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Transplantation, Autologous | 2023 |
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Immunoconjugates; Lymphoma; Neoplasm Recurrence, Local; Treatment Outcome | 2022 |
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2022 |
LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Methotrexate; Prednisolone; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carboplatin; Etoposide; Female; HIV; HIV Infections; Humans; Ifosfamide; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Oncolytic Virotherapy; Recurrence; Rituximab; Viral Load | 2018 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Management; Double-Blind Method; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Rituximab; Young Adult | 2016 |
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mouthwashes; Phytohemagglutinins; Pilot Projects; Placebos; Recombinant Proteins; Stomatitis | 2009 |
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Feasibility Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Lymphoma; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Societies, Medical; Time Factors; Vincristine; Young Adult | 2010 |
Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2011 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cytarabine; Dacarbazine; Diffusion Magnetic Resonance Imaging; Etoposide; Female; Humans; Immunotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Rituximab; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Synergism; Etoposide; Female; Humans; Hydroxamic Acids; Ifosfamide; Lymphoma; Male; Middle Aged; Rituximab; Vorinostat | 2013 |
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Stem Cells; Time Factors | 2002 |
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2003 |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carrier State; Cyclophosphamide; Epirubicin; Etoposide; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma; Male; Middle Aged; Prednisolone; Risk Factors; Survival Analysis; Treatment Outcome; Virus Activation | 2003 |
Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Incidence; Leukemia; Lymphoma; Male; Middle Aged; Neoplasms, Second Primary; Neural Tube Defects; Peripheral Blood Stem Cell Transplantation; Probability; Transplantation, Autologous | 2004 |
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Leukapheresis; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Scandinavian and Nordic Countries; Treatment Outcome | 2004 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2004 |
Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children.
Topics: Acute Disease; Adolescent; Albuminuria; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Creatinine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Glomerular Filtration Rate; Humans; Kidney Tubules; Leukemia; Lymphoma; Methotrexate; Neoplasms; Neuroblastoma; Osteosarcoma; Proteinuria; Rhabdomyosarcoma; Vincristine | 2004 |
Long-term results of dose density therapy in patients with aggressive lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Humans; Ifosfamide; Longitudinal Studies; Lymphoma; Mesna; Methotrexate; Middle Aged; Prednisone; Survival Analysis; Treatment Failure; Treatment Outcome; Vincristine | 2005 |
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infant; Interleukin-11; Lymphoma; Male; Neoplasms; Platelet Count; Recombinant Proteins; Thrombocytopenia | 2005 |
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis | 2005 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous | 2004 |
[An early phase II clinical study of YM 294 (rhlL-11) in patients with solid tumors and malignant lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administration Schedule; Edema; Etoposide; Female; Fever; Humans; Interleukin-11; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Platelet Count; Recombinant Proteins; Thrombocytopenia | 2005 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 2005 |
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with po
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2006 |
Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Prognosis; Remission Induction; Treatment Outcome; Vincristine | 2006 |
Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
Topics: Antineoplastic Agents; Cyclophosphamide; Etoposide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2006 |
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Recurrence; Stem Cells; Time Factors; Vinblastine; Vinorelbine | 2006 |
Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Lymphoma; Male; Methotrexate; Middle Aged; Osmosis; Ovarian Neoplasms; Prospective Studies; Survival Rate | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Sepsis; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2007 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Remission Induction; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Prednisone; Procarbazine; Retrospective Studies; Salvage Therapy; Survival Analysis; Vincristine | 2007 |
Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Leukapheresis; Lymphoma; Male; Middle Aged; Outpatients; Stem Cell Transplantation; Stem Cells; Treatment Outcome | 2007 |
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Humans; Lymphoma; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Time Factors | 2008 |
VP-16-213 (etoposide): the mandrake root from Issyk-Kul.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Cycle; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dysgerminoma; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Mice; Podophyllotoxin | 1982 |
[New antineoplastic drugs of the podophyllotoxin derivative group].
Topics: Adult; Child; Clinical Trials as Topic; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1983 |
[Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukemia; Leukopenia; Lymphoma; Male; Middle Aged; Nausea; Podophyllotoxin; Prednisolone; Thrombocytosis; Vincristine | 1984 |
Cis-dichlorodiammineplatinum (II), VP 16-213, and prednisone (DVP regimen) in the treatment of pretreated advanced malignant lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Podophyllotoxin; Prednisone | 1982 |
A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Etoposide; Humans; Leucovorin; Leukocyte Count; Lymphoma; Mechlorethamine; Methotrexate; Nutrition Disorders; Parenteral Nutrition; Platelet Count; Prednisone; Procarbazine; Prospective Studies; Random Allocation; Serum Albumin; Vincristine | 1981 |
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutropenia; Neutrophils; Prospective Studies; Recombinant Proteins; Survival Rate; Transplantation, Autologous | 1994 |
[Peripheral blood stem cell collection with high dose etoposide].
Topics: Adult; Aged; Blood Component Removal; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1995 |
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Palliative Care; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia | 1995 |
Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies.
Topics: Adolescent; Adult; Antigens, CD34; Colony-Forming Units Assay; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged | 1994 |
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta 2-Microglobulin; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Lymphoma; Polymerase Chain Reaction; Prednisone; RNA, Messenger; RNA, Neoplasm; Time Factors; Vincristine | 1995 |
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Humans; Hypotension; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Platelet Count; Prednisone; Sarcoma; Stereoisomerism; Verapamil; Vincristine | 1995 |
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymerase Chain Reaction; Prednisone; Remission Induction; Stereoisomerism; Verapamil; Vincristine | 1995 |
Therapeutic strategies in intermediate grade lymphomas in elderly patients. The Italian Multiregional non Hodgkin's Lymphoma Study Group (IMRNHLSG).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Epirubicin; Etoposide; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Prednisone; Recombinant Proteins; Survival Analysis; Time Factors; Vinblastine | 1993 |
Bone marrow purging with etoposide/methylprednisolone in patients undergoing autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow Purging; Bone Marrow Transplantation; Child; Etoposide; Humans; Leukemia; Leukocyte Count; Lymphoma; Methylprednisolone; Middle Aged; Neutrophils; Platelet Count; Transplantation, Autologous | 1994 |
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Biological Availability; Drug Administration Schedule; Etoposide; Humans; Injections, Intravenous; Lymphoma; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Organophosphorus Compounds; Prodrugs | 1995 |
A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lung Diseases, Interstitial; Lymphoma; Middle Aged; Transplantation, Autologous; Treatment Outcome | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Transplantation, Homologous | 1995 |
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy | 1994 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Hypotension; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous | 1994 |
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Prognosis; Recurrence; Remission Induction; Survival Rate | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone | 1994 |
Interleukin-3 enhances the endogenous leukotriene production.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Humans; Ifosfamide; Interleukin-3; Leukocyte Count; Leukotriene B4; Leukotrienes; Lymphoma; Recombinant Proteins | 1993 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granisetron; Humans; Indazoles; Lymphoma; Male; Middle Aged; Mitoxantrone; Nausea; Vomiting | 1993 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure | 1995 |
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1995 |
Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Child; Etoposide; Female; Germinoma; Glioblastoma; Humans; Lymphoma; Male; Middle Aged; Neoplasm Metastasis; Neuroectodermal Tumors, Primitive; Oligodendroglioma; Tomography, X-Ray Computed | 1995 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation | 1996 |
[Clinical trial of oral etoposide in the treatment of malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Child; Etoposide; Female; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Ovarian Neoplasms; Prospective Studies | 1995 |
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cell Movement; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma; Melphalan; Middle Aged; Phospholipid Ethers; Risk Factors; Transplantation Conditioning | 1996 |
Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukocyte Count; Lymphoma; Male; Middle Aged; Recombinant Proteins; Salvage Therapy | 1997 |
[Long-term follow up of aggressive lymphoma patients treated with CAMBO-VIP--clinical significance of a residual mass after otherwise successful chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Time Factors; Vincristine | 1998 |
A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide, and granulocyte colony-stimulating factor with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Survival Analysis | 1998 |
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Recurrence; Transplantation Conditioning | 1999 |
Telomerase activity in central nervous system malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Catalytic Domain; Combined Modality Therapy; DNA-Binding Proteins; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Prednisolone; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA; Survival Analysis; Telomerase; Vincristine | 1999 |
ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Matched-Pair Analysis; Methylprednisolone | 2000 |
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2000 |
[Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Dexamethasone; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma; Male; Melphalan; Nausea; Ondansetron; Serotonin Antagonists; Transplantation, Autologous; Tropisetron; Vomiting | 2000 |
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma; Methotrexate; Middle Aged; Mitoguazone; Premedication; Recurrence; Transplantation, Autologous | 2001 |
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome | 2001 |
Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kinetics; Lymphoma; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Prognosis; Salvage Therapy; Treatment Outcome | 2001 |
Effective progenitor cell mobilization in lymphoproliferative disorders using ifosfamide, epirubicin and etoposide (IEV).
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Lymphoma; Lymphoproliferative Disorders; Male; Middle Aged; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2001 |
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2001 |
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi-Square Distribution; Cisplatin; Cost-Benefit Analysis; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Recurrence; Statistics, Nonparametric; Survival Rate; Transplantation, Autologous | 2001 |
Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Lymphoma; Middle Aged; Organophosphorus Compounds; Prodrugs; Therapeutic Equivalency | 2001 |
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Topics: Alopecia; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Humans; Leukemia; Leukopenia; Lung Neoplasms; Lymphoma; Podophyllotoxin; Teniposide | 1979 |
Podophyllotoxin derivative VP 16-213.
Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma | 1979 |
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lymphoma; Middle Aged; Recurrence; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1992 |
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Neoplasms; Survival Analysis; Transplantation, Autologous | 1992 |
BEAM autografting in lymphoma--experience at one centre.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation, Autologous | 1992 |
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
Treatment of malignant lymphomas with very-high-dose CVB followed by transplantation of autologous blood stem cells collected after mobilizing chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Middle Aged; Pancytopenia; Pulmonary Fibrosis; Radiotherapy; Remission Induction; Transplantation, Autologous; Vindesine | 1991 |
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Lymphoma; Middle Aged; Mitoguazone; Mitoxantrone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Vinblastine | 1991 |
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Mitoguazone; Prognosis | 1991 |
Treatment of pediatric malignant tumors with VP-16. West Japan Pediatric Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Histiocytosis; Humans; Infant; Leukemia, Myeloid, Acute; Lymphoma; Neoplasms; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lysophosphatidylcholines; Methylprednisolone; Neoplasms, Experimental; Phospholipid Ethers; Pyrimidinones; Transplantation, Autologous; Transplantation, Isogeneic | 1986 |
Etoposide (VP-16-213). Current status of an active anticancer drug.
Topics: Animals; Carcinoma, Small Cell; Clinical Trials as Topic; DNA; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Podophyllotoxin; Testicular Neoplasms; Tissue Distribution | 1985 |
[Phase I clinical study of NK 171 (etoposide)].
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Podophyllotoxin | 1985 |
[Evaluation of the effectiveness of Vepeside (VP-16-213) in the treatment of drug-resistant recurrences of malignant lymphatic neoplasms].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Resistance; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Recurrence | 1987 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Hydroxyurea; Ifosfamide; Lymphoma; Male; Middle Aged; Recurrence | 1985 |
VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Podophyllotoxin; Prognosis; Prospective Studies; Random Allocation | 1985 |
284 other study(ies) available for etoposide and Lymphoma
| Article | Year |
|---|---|
Synthesis of novel alkyltriazole tagged pyrido[2,3-d]pyrimidine derivatives and their anticancer activity.
Topics: Alkylation; Antineoplastic Agents; Azides; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cyclization; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Leukemia, Monocytic, Acute; Lymphoma; Pyrimidines; Structure-Activity Relationship; Triazoles | 2011 |
High D-index during mobilization predicts poor mobilization of CD34+ cells after anti-lymphoma salvage chemotherapy.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Young Adult | 2022 |
Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.
Topics: Epstein-Barr Virus Infections; Etoposide; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Retrospective Studies | 2021 |
Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Neutrophils; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children.
Topics: Child; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Retrospective Studies | 2022 |
[Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2022 |
A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Semustine; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2022 |
High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2022 |
The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bendamustine Hydrochloride; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Etoposide; Humans; Lymphoma; Lymphoma, T-Cell; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Ribose; Tumor Suppressor Protein p53 | 2022 |
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma; Lymphoma, T-Cell; Retrospective Studies; Treatment Outcome | 2022 |
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; COVID-19; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; In Situ Hybridization, Fluorescence; Lymphoma; Lymphoma, B-Cell; Prednisone; Retrospective Studies; Rituximab; Transplantation, Autologous; Vincristine | 2022 |
Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH.
Topics: Dexamethasone; Etoposide; Humans; Lactate Dehydrogenases; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Lymphoma, T-Cell; Retrospective Studies | 2022 |
[Analysis of Related Factors of Autologous Peripheral Hematopoietic Stem Cell Mobilization in Patients with Lymphoma and Myeloma].
Topics: Etoposide; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Multiple Myeloma; Retrospective Studies | 2022 |
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2023 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2023 |
ATM activity in T cells is critical for immune surveillance of lymphoma in vivo.
Topics: Alleles; Animals; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Etoposide; Hematopoietic Stem Cell Transplantation; Lymphoma; Mice; Mice, Knockout; T-Lymphocytes; Transplantation, Homologous; Treatment Outcome | 2020 |
Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphoma; Male; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2020 |
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Progression-Free Survival; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2020 |
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
Topics: Animals; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Chickens; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Female; Histones; Humans; Indans; Isoquinolines; Lung Neoplasms; Lymphoma; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Poultry Diseases; Random Allocation; Recombinant Proteins; Substrate Specificity; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2020 |
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Retrospective Studies | 2020 |
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Multicenter Studies as Topic; Prednisone; Retrospective Studies; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine; Young Adult | 2020 |
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine; Lymphoma; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2021 |
[A Case of Adult T-Cell Leukemia/Lymphoma with Severe Hand-Foot Syndrome during Administration of Modified LSG15 Regimen].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hand-Foot Syndrome; Humans; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Middle Aged; Nitrosourea Compounds; Prednisolone; Vincristine; Vindesine | 2020 |
Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism.
Topics: Apoptosis; Cell Proliferation; Cisplatin; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Mitochondria; Oxidation-Reduction; Oxidative Stress; Phosphorylation; Primary Cell Culture; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Serine | 2020 |
[IEAC versus CEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for lymphoma: analysis of efficacy and safety in 106 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation, Autologous | 2020 |
Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy-intolerant lymphoma patients.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Feasibility Studies; Humans; Lymphoma; Piperazines; Prospective Studies | 2021 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Endocytosis; Etoposide; Humans; Hyaluronic Acid; Inhibitory Concentration 50; Lipids; Lymphoma; Male; Mice, Inbred C57BL; Nanoparticles; Particle Size; Proton Magnetic Resonance Spectroscopy; Static Electricity; Succinates; tat Gene Products, Human Immunodeficiency Virus; Tissue Distribution; Tocopherols | 2017 |
Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Etoposide; Lymphoma; Neoplasm Grading; Neoplasm Staging; Organophosphorus Compounds; Treatment Outcome; Tumor Burden | 2017 |
Proteomic characterization of EL4 lymphoma-derived tumors upon chemotherapy treatment reveals potential roles for lysosomes and caspase-6 during tumor cell death in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 6; Cyclophosphamide; Etoposide; Female; Lymphoma; Lysosomes; Mice; Mice, Inbred C57BL; Proteome; Proteomics; Tumor Cells, Cultured | 2017 |
Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Incidence; Kaplan-Meier Estimate; Kidney Diseases; Lymphoma; Male; Methylprednisolone; Middle Aged; Outpatients; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Young Adult | 2017 |
[Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Prednisone; Rituximab; Vincristine | 2017 |
Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Blood Component Removal; Etoposide; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Patient Readmission; Peripheral Blood Stem Cells; Time Factors; Transplantation, Autologous; Young Adult | 2018 |
Pregnancy-associated hemophagocytic lymphohistiocytosis secondary to NK/T cells lymphoma: A case report and literature review.
Topics: Adult; Antineoplastic Agents; Bone Marrow Examination; Dexamethasone; Diagnosis, Differential; Etoposide; Fatal Outcome; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Natural Killer T-Cells; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Rituximab; Spleen | 2017 |
Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem C
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Energy Intake; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Nitrosourea Compounds; Nutritional Physiological Phenomena; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cytarabine; Etoposide; Humans; Lymphoma; Remission Induction; Survival Analysis; Treatment Outcome | 2018 |
Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Chemoradiotherapy; Consolidation Chemotherapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Male; Mediastinal Neoplasms; Prednisone; Remission Induction; Rituximab; Stem Cell Transplantation; Vincristine | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2018 |
A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lomustine; Lymphoma; Male; Palliative Care; Prednisolone; Recurrence; Retrospective Studies; Rituximab | 2019 |
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning | 2019 |
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma; Male; Middle Aged; Prospective Studies; Registries; Stem Cell Transplantation; Survival Rate; Thiotepa | 2019 |
CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Incidence; Lymphoma; Male; Middle Aged; Neurotoxicity Syndromes; Retrospective Studies; Thiamine | 2020 |
Fatal cisplatin overdose in the treatment of mediastinal lymphoma with the ESHAP regimen - analysis of the causes of the adverse drug event.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Overdose; Etoposide; Fatal Outcome; Female; Humans; Lymphoma; Mediastinal Neoplasms; Medication Errors; Methylprednisolone | 2013 |
Analysis of image heterogeneity using 2D Minkowski functionals detects tumor responses to treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Etoposide; Female; Image Interpretation, Computer-Assisted; Lymphoma; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neoplasm Staging; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Stilbenes; Treatment Outcome | 2014 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection.
Topics: Adjuvants, Immunologic; Animals; Antibodies; Antigens, Ly; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokines; Disease Models, Animal; Etoposide; Flow Cytometry; Gene Expression Regulation, Neoplastic; Interleukin-2 Receptor alpha Subunit; Killer Cells, Natural; Lymphoma; Memory Disorders; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; NK Cell Lectin-Like Receptor Subfamily B; Oligodeoxyribonucleotides; T-Lymphocytes, Regulatory; Time Factors; Toll-Like Receptor 9 | 2014 |
Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Bilirubin; C-Reactive Protein; Etoposide; Female; Ferritins; Fever; France; Glucocorticoids; Hemoglobins; Humans; Immunocompromised Host; L-Lactate Dehydrogenase; Leukocyte Count; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Middle Aged; Multiple Organ Failure; Platelet Count; Retrospective Studies; Sodium; Triglycerides | 2014 |
Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Transplantation Conditioning; Young Adult | 2014 |
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2014 |
Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Combined Modality Therapy; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous; Young Adult | 2014 |
Cytotoxic effect of the biotechnologically-derived justicidin B on human lymphoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Dioxolanes; Etoposide; Female; Humans; Lignans; Lymphoma; Male; Mice; NF-kappa B | 2014 |
[Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Herpesvirus 8, Human; Humans; Lymphoma; Lymphoma, Primary Effusion; Male; Piperazines; Rituximab | 2014 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2015 |
Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; China; Cyclosporine; Etoposide; Female; Glucocorticoids; Health Knowledge, Attitudes, Practice; Herpesvirus 4, Human; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Middle Aged; Retrospective Studies; Young Adult | 2015 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Combined Modality Therapy; Cyclophosphamide; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobins; Humans; Iron; Jehovah's Witnesses; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Vitamin K 1; Young Adult | 2015 |
Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.
Topics: Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Menopause, Premature; Middle Aged; Ovarian Function Tests; Prednisone; Primary Ovarian Insufficiency; Surveys and Questionnaires; Survivors; Vincristine | 2015 |
[Efficacy of R±BEACOP regimen in patients with
poor-prognosis lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Rituximab; Vincristine | 2015 |
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Carboplatin; Child; Cisplatin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2015 |
Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy | 2016 |
The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2016 |
Treating Adults with Hodgkin Lymphoma in the Developing World: a Hospital-Based Cohort Study from Armenia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Armenia; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Developed Countries; Doxorubicin; Etoposide; Female; Hodgkin Disease; Hospitals; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Retrospective Studies; Vinblastine; Vincristine; Young Adult | 2016 |
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Liver Function Tests; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Febrile Neutropenia; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Nausea; Nitrosourea Compounds; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Mediastinal Neoplasms; Prednisone; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2017 |
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Methotrexate; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2017 |
Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Inpatients; Length of Stay; Leukemia; Lymphoma; Male; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 2017 |
Topoisomerase II inhibition involves characteristic chromosomal expression patterns.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Chlorodiphenyl (54% Chlorine); Chromosome Mapping; Chromosomes, Human; Chromosomes, Mammalian; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fluoroquinolones; Gene Expression Regulation; Hepatocytes; Humans; Lymphocytes; Lymphoma; Mice; Mice, Transgenic; Naphthyridines; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-myc; Topoisomerase II Inhibitors; Transcription Factors; Transcription, Genetic | 2008 |
A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carbon Isotopes; Carbon Radioisotopes; Cell Line, Tumor; Etoposide; Female; Flow Cytometry; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Lactates; Lymphoma; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Poly(ADP-ribose) Polymerases; Positron-Emission Tomography; Pyruvates; Treatment Outcome | 2009 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2009 |
Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carbon Isotopes; Etoposide; Female; Fumarate Hydratase; Fumarates; Lymphoma; Malates; Mice; Mice, Inbred C57BL; Necrosis; Neoplasm Transplantation; Neoplasms; Nuclear Magnetic Resonance, Biomolecular; Tissue Extracts; Treatment Outcome | 2009 |
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prednisone; Radiotherapy; Retrospective Studies; Treatment Outcome; Vincristine | 2010 |
ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cisplatin; Colony-Stimulating Factors; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Remission Induction; Rituximab | 2010 |
Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Blood Component Removal; Databases, Factual; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Platelet Count; Recovery of Function; Retrospective Studies; Survival Rate; Transplantation, Autologous | 2011 |
Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Young Adult | 2012 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Rituximab; Transplantation, Autologous; Young Adult | 2011 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Salvage Therapy; Thiotepa; Young Adult | 2011 |
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Chemoradiotherapy; Cognition Disorders; Dexamethasone; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Lymphoma; Male; Middle Aged; Outcome Assessment, Health Care; Radiotherapy; Retrospective Studies; Survivors; Young Adult | 2011 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Mediastinum; Middle Aged; Pneumonia; Radiation, Ionizing; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2012 |
BCNU-associated pneumonitis: portrait of a toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Pneumonia; Stem Cell Transplantation | 2012 |
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-15; Interleukin-7; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Prednisone; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Vincristine | 2012 |
Induction of apoptosis in Eμ-myc lymphoma cells in vitro and in vivo through calpain inhibition.
Topics: Acrylates; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Calcium-Binding Proteins; Calpain; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Etoposide; Humans; Lymphoma; Mice; Mice, Transgenic | 2012 |
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cyclophosphamide; Drug Administration Routes; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Orbital plasmablastic lymphoma with remission following chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Multimodal Imaging; Orbital Neoplasms; Polyethylene Glycols; Positron-Emission Tomography; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recombinant Proteins; Remission Induction; Tomography, X-Ray Computed; Vincristine | 2011 |
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Endothelial Cells; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Prednisone; Procarbazine; Receptors, Vascular Endothelial Growth Factor; Secondary Prevention; Vascular Endothelial Growth Factor A | 2012 |
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Topics: Aniline Compounds; Animals; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-X Protein; Biphenyl Compounds; Cell Death; Cytoprotection; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Membrane Proteins; Mice; Molecular Targeted Therapy; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2012 |
Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Etoposide; Female; Lymphoma; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondrial Proteins; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Tumor Suppressor Protein p53 | 2012 |
The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Base Sequence; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulation; Etoposide; Gene Expression; Green Fluorescent Proteins; Humans; Imidazoles; Lymphoma; MicroRNAs; Piperazines; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; RNA Interference; Transfection; Tumor Suppressor Protein p53 | 2012 |
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2002 |
Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Data Collection; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2002 |
VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Mantle-Cell; Middle Aged; Paclitaxel; Prednisone; Rituximab; Time Factors; Topotecan; Treatment Outcome; Vincristine | 2002 |
Excellent long-term survival in patients with early-stage primary bone lymphoma treated with doxorubicin-based chemotherapy and local radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Prednisone; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome; Vincristine | 2002 |
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Etoposide; Humans; Lymphoma; Male; Melanoma, Experimental; Mice; Mice, Inbred CBA; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Peptides, Cyclic; Somatostatin; Xenograft Model Antitumor Assays | 2003 |
When lymphoma and heart failure cross paths.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Echocardiography; Etoposide; Female; Heart Neoplasms; Humans; Lymphoma; Prednisolone; Prednisone; Treatment Outcome; Vincristine | 2003 |
Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Organophosphorus Compounds; Radioimmunotherapy; Recurrence; Rituximab; Time Factors | 2003 |
Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity.
Topics: Animals; Anti-Infective Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Genistein; Lymphoma; Mice; Mutagens; Topoisomerase I Inhibitors | 2003 |
Evaluation for the development of 11q23 rearrangements in lymphoma patients treated with a high dose VP-16 and cyclophosphamide salvage regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Bone Marrow; Chromosome Mapping; Chromosomes, Human, Pair 11; Cyclophosphamide; DNA, Neoplasm; Etoposide; Exons; Female; Gene Rearrangement; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy | 2003 |
Caspase 3-mediated inactivation of rac GTPases promotes drug-induced apoptosis in human lymphoma cells.
Topics: Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspases; Cytoskeleton; Down-Regulation; Etoposide; Genetic Vectors; Humans; Lymphoma; Models, Molecular; Mutagenesis, Site-Directed; Mutation; p21-Activated Kinases; Plasmids; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; rac GTP-Binding Proteins; Recombinant Proteins; Signal Transduction; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured | 2003 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatids; Chromosome Aberrations; Chromosomes; Culture Media; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Humans; Karyotyping; Lymphoma; Mutagens; Vidarabine | 2003 |
Association of intestinal malignant lymphoma and ulcerative colitis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colitis, Ulcerative; Colonoscopy; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Lymphoma; Methotrexate; Peripheral Blood Stem Cell Transplantation; Sigmoid Neoplasms; Vincristine | 2003 |
Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Humans; Lymphoma; Platelet Transfusion; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2004 |
[A case of isolated hepatic malignant lymphoma representing characteristic findings on radiological imaging].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Irinotecan; L-Lactate Dehydrogenase; Liver Neoplasms; Lymphoma; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prednisolone; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2003 |
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; bcl-X Protein; Caspase 3; Caspase 8; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Immunoblotting; Jurkat Cells; Ligands; Lymphoma; Membrane Glycoproteins; Membrane Potentials; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-bcl-2; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75.
Topics: Animals; Apoptosis; bcl-Associated Death Protein; Carrier Proteins; Caspases; Cell Line, Tumor; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Humans; Lymphoma; Mice; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; rac1 GTP-Binding Protein; Recombinant Fusion Proteins; Serine; Signal Transduction | 2004 |
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Interleukin-10; Interleukin-2; Interleukin-6; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Prednisone; Prognosis; Regression Analysis; Time Factors; Treatment Outcome; Vincristine | 2004 |
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2005 |
Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Topics: Alleles; Animals; Apoptosis; B-Lymphocytes; bcl-X Protein; Blotting, Western; Bone Marrow Cells; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Enhancer Elements, Genetic; Etoposide; Flow Cytometry; Gene Rearrangement; Genes, Regulator; Genetic Vectors; Immunoglobulin Heavy Chains; Lymphoma; Mice; Mice, Transgenic; Models, Genetic; Nuclear Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins c-myc; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Spleen; Time Factors; Transfection | 2005 |
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Pneumonia; Prednisone; Procarbazine; Retrospective Studies; Sepsis; Vincristine | 2005 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine | 2005 |
Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chelating Agents; Cysteine; Drug Carriers; Etoposide; Humans; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Liposomes; Lymphoma; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Palmitic Acid; Particle Size; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Tin Compounds; Tissue Distribution | 2005 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infections; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2005 |
Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis.
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; bcl-X Protein; Binding Sites; Blotting, Western; Caspase 9; Caspases; Cell Line; Cell Line, Tumor; Cell Survival; Cloning, Molecular; Dexamethasone; DNA-Binding Proteins; Etoposide; Gene Expression Regulation, Enzymologic; Glucocorticoids; Kinetics; Lymphoma; Mice; Mutation; Oligonucleotides, Antisense; Promoter Regions, Genetic; Proteins; Proto-Oncogene Proteins c-bcl-2; Thymus Neoplasms; Time Factors; Transcription Factors; Transfection | 2005 |
1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Count; Cell Line, Tumor; Etoposide; Female; Lipid Metabolism; Lymphoma; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Protons; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic | 2005 |
Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Breast Neoplasms; Caspase 3; Caspase Inhibitors; Caspases; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Guanine Nucleotide Dissociation Inhibitors; Humans; Lymphoma; Molecular Sequence Data; Mutation; rac1 GTP-Binding Protein; rho Guanine Nucleotide Dissociation Inhibitor alpha; rho-Specific Guanine Nucleotide Dissociation Inhibitors; RNA Interference; RNA, Small Interfering; Transfection | 2005 |
[Tandem autotransplants of peripheral blood stem cells following sequential high-dose CHOEP chemotherapy for aggressive lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisolone; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Culicidae; Epstein-Barr Virus Infections; Etoposide; Glyoxal; Humans; Hypersensitivity; Ifosfamide; Insect Bites and Stings; Killer Cells, Natural; Lymph Nodes; Lymphocytes; Lymphoma; Male; Prednimustine; Skin | 2006 |
Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 6; Caspases; Cell Line, Tumor; Chickens; Etoposide; Gene Expression Regulation, Neoplastic; Lymphoma | 2006 |
Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Etoposide; Fatal Outcome; Female; Hemoglobins; Humans; Idarubicin; Ifosfamide; Leukoencephalopathy, Progressive Multifocal; Lymphoma; Magnetic Resonance Imaging | 2005 |
[Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Recombinant Proteins; Rituximab; Vincristine | 2006 |
Correlation between decreased sensitivity of the Daudi lymphoma cells to VP-16-induced apoptosis and deficiency in DNAS1L3 expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; bcl-Associated Death Protein; Calcium; Caspase 3; Caspases; Cell Line, Tumor; Deoxyribonucleases; DNA; DNA Damage; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Endodeoxyribonucleases; Enzyme Activation; Etoposide; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Lymphoma; Magnesium; Membrane Potentials; Nucleosomes; Poly-ADP-Ribose Binding Proteins; Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transfection; U937 Cells | 2006 |
Enhanced delivery of etoposide to Dalton's lymphoma in mice through polysorbate 20 micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Stability; Etoposide; Injections, Subcutaneous; Lymphoma; Mice; Mice, Inbred BALB C; Micelles; Particle Size; Polysorbates; Technetium; Tissue Distribution | 2006 |
Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice.
Topics: Animals; Apoptosis; Disease Models, Animal; Etoposide; Lymphoma; Mice; Mice, Inbred BALB C; Micronucleus Tests; Nanostructures; Treatment Outcome | 2006 |
Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Retrospective Studies; Time Factors; Vincristine | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carotid Artery, Internal; Catheterization, Peripheral; Cyclophosphamide; Cytarabine; Etoposide; Female; Fluorescein Angiography; Humans; Injections, Spinal; Lymphoma; Male; Mannitol; Methotrexate; Middle Aged; Pigment Epithelium of Eye; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Vertebral Artery | 2007 |
Mobilization regimens prior to stem-cell collection in patients with lymphoma: how to choose?
Topics: Antigens, CD34; Bone Marrow Cells; Chemokine CXCL12; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lymphoma; Recurrence; Risk; Stem Cell Transplantation; Treatment Outcome | 2007 |
[Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation | 2007 |
[Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbon Isotopes; Cell Death; Cell Line, Tumor; Etoposide; Lactate Dehydrogenases; Lactic Acid; Lymphoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Neoplasm Transplantation; Pyruvic Acid | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Nimustine; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphamide; Cytarabine; Etoposide; Fluorescein Angiography; Humans; Injections, Spinal; Lymphoma; Mannitol; Methotrexate; Pigment Epithelium of Eye; Retinal Diseases | 2007 |
Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent.
Topics: Analysis of Variance; Animals; Apoptosis; Carbohydrate Sulfotransferases; Contrast Media; Etoposide; Female; Flow Cytometry; Fluorescein; Gadolinium DTPA; In Situ Nick-End Labeling; Liposomes; Lymphoma; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Phosphatidylserines; Prospective Studies; Protein Binding; Sulfotransferases; Tumor Cells, Cultured | 2008 |
[High-dose ifosfamide and etoposide regimen as salvage and mobilization therapy for patients with lymphoma].
Topics: Adult; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Salvage Therapy | 2008 |
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Evaluation; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2008 |
Results of treatment of 112 cases of primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cognition; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Leucovorin; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine | 2008 |
Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Radiography, Abdominal; Remission, Spontaneous; Time Factors; Vincristine | 1983 |
Current problems in the management of non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma; Methotrexate; Prednisone; Vincristine | 1984 |
High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lymphoma; Male; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1983 |
[A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance; Etoposide; Humans; Lymphoma; Podophyllotoxin; Vincristine | 1984 |
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Humans; Leucovorin; Leukopenia; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Vincristine | 1983 |
Erythema and desquamation after high-dose methotrexate.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Erythema; Etoposide; Female; Humans; Leucovorin; Lymphoma; Methotrexate; Prednisone | 1983 |
Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Lymphoma | 1983 |
[Phase I study of an oral administration of VP 16-213].
Topics: Administration, Oral; Adult; Aged; Capsules; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Podophyllotoxin | 1983 |
[Phase II study of etoposide in malignant lymphoma].
Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Podophyllotoxin | 1984 |
Etoposide as single agent and in combination with cis-platinum for malignant lymphomas.
Topics: Adult; Aged; Blood; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lymphoma; Middle Aged; Podophyllotoxin | 1982 |
Cis-dichlorodiammineplatinum (II) (cis-platinum) and etoposide for patients with refractory lymphomas.
Topics: Adult; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Podophyllotoxin | 1982 |
Interaction of VP16-213 with the DNA repair antagonist chloroquine.
Topics: Animals; Chloroquine; DNA Repair; Drug Interactions; Etoposide; Female; Lymphoma; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Podophyllotoxin; Vincristine | 1982 |
Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin | 1982 |
IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Inflammation; Lymphoma; Methotrexate; Mucous Membrane; Neutropenia; Podophyllotoxin; Recurrence | 1982 |
[Etoposide: VP-16].
Topics: Etoposide; Humans; Lung Neoplasms; Lymphoma; Neoplasms; Podophyllotoxin | 1982 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Length of Stay; Leukapheresis; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Vincristine | 1993 |
Secondary myelodysplastic syndrome following bone marrow transplantation: report of two cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma; Male; Methotrexate; Myelodysplastic Syndromes; Prednisone; Procarbazine; Rectal Neoplasms; Risk Factors; Seminoma; Testicular Neoplasms; Transplantation, Autologous; Vincristine | 1994 |
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphoma; Mitoxantrone; Salvage Therapy; Slovakia | 1995 |
High grade malignant lymphoma with clinical characteristics and immunophenotype of natural killer cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunophenotyping; Killer Cells, Natural; Leukocyte Count; Lymphoma; Male; Prednisone; Spleen; Splenectomy; Thrombocytopenia; Vincristine | 1995 |
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia; Lung; Lymphoma; Male; Middle Aged; Recurrence; Skin; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1995 |
[Peripheral blood stem cell transplantation in adult patients].
Topics: Adolescent; Adult; Blood Cell Count; Cell Separation; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
Predicting neutropenia after chemotherapy for lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukocyte Count; Lymphoma; Male; Mechlorethamine; Middle Aged; Neutropenia; Predictive Value of Tests; Prednisolone; Procarbazine; Retrospective Studies; Risk Factors; Thrombocytopenia; Vinblastine; Vincristine | 1993 |
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lymphoma; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prednisone; Recombinant Proteins; Vincristine | 1993 |
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Salvage Therapy; Time Factors | 1993 |
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma; Chromosome Aberrations; Chromosome Disorders; Cisplatin; Etoposide; Female; Germinoma; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Retroperitoneal Neoplasms; Testicular Neoplasms; Treatment Outcome | 1995 |
Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Transplantation, Autologous | 1994 |
[Therapeutic effects of peripheral blood stem cell transplantation following combination chemotherapy using ranimustine, cytarabine, etoposide and cyclophosphamide for patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Male; Middle Aged; Nitrosourea Compounds | 1994 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; Etoposide; Female; Flow Cytometry; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Lymphocyte Subsets; Lymphoma; Male; Middle Aged; Nitrosourea Compounds; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Multiple Myeloma; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses.
Topics: Animals; Bone Marrow; Etoposide; Humans; Lymphoma; Male; Methylnitrosourea; Mice; Micronucleus Tests; Mutagenicity Tests; Salmonella; Tumor Cells, Cultured | 1994 |
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Lymphoma; Male; Melphalan; Spermatozoa; Transplantation, Autologous | 1994 |
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Mesna; Methylprednisolone Hemisuccinate; Mitoxantrone; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate | 1994 |
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hemorrhage; Humans; Leukemia; Lung Diseases; Lymphoma; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia; Lung Diseases, Interstitial; Lymphoma; Male; Middle Aged; Retrospective Studies; Skin Diseases; Whole-Body Irradiation | 1994 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous | 1993 |
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Treatment Outcome | 1993 |
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Lymphoma; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Treatment Outcome | 1993 |
Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Glomerular Filtration Rate; Hemolytic-Uremic Syndrome; Humans; Kidney; Lymphoma; Male; Middle Aged; Transplantation, Autologous; Whole-Body Irradiation | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Non-Hodgkin; Macrophages; Male; Melphalan | 1995 |
[A case of early gastric cancer transformed from adenoma by chemotherapy and radiotherapy].
Topics: Adenoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Lymphoma; Male; Neoplasms, Second Primary; Prednisolone; Stomach Neoplasms; Tegafur; Uracil; Vincristine | 1996 |
Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate | 1996 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Liver Function Tests; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous | 1996 |
[Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Leukemia; Lymphoma; Tumor Cells, Cultured | 1996 |
Higher in vivo protein binding of etoposide in children compared with adult cancer patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Child; Child, Preschool; Etoposide; Female; Histiocytic Sarcoma; Humans; Infant; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Male; Middle Aged; Multiple Myeloma; Oligodendroglioma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Reference Values; Serum Albumin | 1996 |
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1996 |
Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Camptothecin; Cloning, Molecular; DNA, Neoplasm; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Heterogeneous-Nuclear Ribonucleoproteins; Lymphoma; Mice; Molecular Sequence Data; Neoplasm Proteins; Radiation Leukemia Virus; Ribonucleoproteins; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
[Bilateral highly malignant centroblastic lymphoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Mammography; Middle Aged; Neoplasms, Multiple Primary; Prednisone; Stem Cell Transplantation; Tomography, X-Ray Computed; Vincristine | 1996 |
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Breast Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Lung Neoplasms; Lymphoma; Neoplasm Proteins; Polymerase Chain Reaction; Prednisone; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Verapamil; Vincristine | 1997 |
Low levels of serum soluble c-kit relates to delayed engraftment after bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Graft Rejection; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Proto-Oncogene Proteins c-kit; Transplantation Conditioning; Whole-Body Irradiation | 1997 |
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.
Topics: Adult; Aged; Cyclophosphamide; Drug Combinations; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Multivariate Analysis; Transplantation Conditioning | 1997 |
Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated Bcl-2 protein.
Topics: Apoptosis; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; DNA Fragmentation; Drug Synergism; Etoposide; Humans; Lymphoma; Naphthalenes; Phosphoproteins; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; Translocation, Genetic; Tumor Cells, Cultured; Up-Regulation | 1997 |
Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle; Cells, Cultured; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Gene Expression Regulation; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Heterogeneous-Nuclear Ribonucleoproteins; Lymphoma; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Razoxane; Ribonucleoproteins; T-Lymphocytes; Thymus Gland; Topoisomerase II Inhibitors | 1997 |
Apoptosis in the absence of cytochrome c accumulation in the cytosol.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Biotin; Bleomycin; Blotting, Western; Camptothecin; Cytochrome c Group; Cytosol; Enzyme Inhibitors; Etoposide; Humans; Hydroxamic Acids; Lymphoma; Microscopy, Fluorescence; Mitochondria; Phalloidine; Poly(ADP-ribose) Polymerases; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine | 1998 |
Treatment of multifocal lymphoma of bone with intensified ProMACE-CytaBOM chemotherapy and involved field radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Prednisone; Survival Analysis; Tomography, X-Ray Computed; Vincristine | 1998 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Partial Thromboplastin Time; Plasminogen; Prednisone; Procarbazine; Protein C; Protein S; Thrombophilia; Time Factors; Vinblastine; Vincristine | 1997 |
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Recombinant Proteins; Retrospective Studies | 1998 |
Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Apoptosis; Caspase Inhibitors; Caspases; Culture Media, Serum-Free; Cycloheximide; Etoposide; Eukaryotic Initiation Factor-4E; fas Receptor; Half-Life; Humans; Jurkat Cells; Lymphoma; Molecular Weight; Neoplasm Proteins; Oligopeptides; Peptide Initiation Factors; Poly(A)-Binding Proteins; Poly(ADP-ribose) Polymerases; Protein Synthesis Inhibitors; RNA-Binding Proteins; Sirolimus; Tumor Cells, Cultured | 1998 |
High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Stem Cells | 1998 |
Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Prognosis; Transplantation, Autologous | 1999 |
Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cisplatin; Etoposide; Female; Glioblastoma; Hematoma; Humans; Infusions, Intra-Arterial; Lymphoma; Male; Middle Aged; Nausea; Retrospective Studies; Vomiting | 1999 |
[Primary lymphoma of the thyroid with contralateral recurrence--case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Citrates; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Female; Gallium; Gallium Radioisotopes; Humans; Ifosfamide; Lymphoma; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Radiopharmaceuticals; Remission Induction; Technetium; Thallium; Thyroid Neoplasms; Thyroidectomy; Vincristine | 1999 |
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Carmustine; Cyclophosphamide; Etoposide; Female; Fever; Hodgkin Disease; Humans; Length of Stay; Lymphoma; Male; Middle Aged; Neutropenia; Ofloxacin; Opportunistic Infections; Rifampin; Salvage Therapy | 1999 |
Bcl-2 expression correlates with apoptosis induction but not tumor growth delay in transplantable murine lymphomas treated with different chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Lymphoma; Male; Mice; Mice, Inbred C3H; Proto-Oncogene Proteins c-bcl-2 | 1999 |
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Radiation-Induced; Lymphoma; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Neoplasms, Second Primary; Odds Ratio; Radiotherapy; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2000 |
Hematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Galpha 16 and CD34.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Epirubicin; Etoposide; Female; Gene Expression; GTP-Binding Protein alpha Subunits, Gq-G11; Hematopoiesis; Heterotrimeric GTP-Binding Proteins; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; RNA, Messenger; Time Factors | 2000 |
Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Count; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Leukapheresis; Lymphoma; Lymphoproliferative Disorders; Male; Middle Aged; Regression Analysis; Salvage Therapy; Time Factors | 2000 |
Epoch-cyclosporin A induces high response rates in relapsed lymphomas.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Humans; Lymphoma; Male; Pilot Projects; Prednisone; Recurrence; Treatment Outcome; Vincristine | 2000 |
Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF.
Topics: Adult; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Middle Aged | 2000 |
Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; B-Lymphocytes; Cell Division; Cell Line, Transformed; Cell Separation; Cyclin D2; Cyclins; Dexamethasone; DNA, Antisense; Down-Regulation; Etoposide; Flow Cytometry; Humans; Immunoblotting; Lymphoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Transforming Growth Factor beta; Tumor Cells, Cultured; Vincristine; Viral Matrix Proteins | 2001 |
Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Blotting, Southern; Blotting, Western; Caspase 2; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell-Free System; Cloning, Molecular; Cytochrome c Group; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Humans; Kinetics; Lymphoma; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Nucleic Acid Synthesis Inhibitors; Precipitin Tests; Protein Binding; Protein Isoforms; Protein Structure, Tertiary; Recombinant Proteins; RNA, Messenger; Sequence Homology, Amino Acid; Time Factors; Tissue Distribution; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Two-Hybrid System Techniques | 2000 |
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization; Killer Cells, Natural; Lymphoma; Male; Methotrexate; Middle Aged; Nose Neoplasms; Prednisone; Radiotherapy; RNA, Viral; Treatment Outcome; Vincristine | 2001 |
Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cesium Radioisotopes; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; DNA-Binding Proteins; Dose-Response Relationship, Radiation; Etoposide; Gamma Rays; Gene Expression Regulation, Enzymologic; Genes, p53; Genes, Tumor Suppressor; Humans; Jurkat Cells; Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vincristine | 2001 |
ICE--an efficient drug combination for stem cell mobilization and high-dose treatment of malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Etoposide; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Neoplasms, Germ Cell and Embryonal; Retrospective Studies; Survival Rate; Therapeutic Equivalency | 2001 |
Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells.
Topics: Adenoviridae; Apoptosis; Cell Division; Cell Line; Etoposide; Flow Cytometry; Gene Transfer Techniques; Genes, p53; Green Fluorescent Proteins; Humans; Immunoblotting; Killer Cells, Natural; Luminescent Proteins; Lymphoma; Microscopy, Fluorescence; Mutation; Necrosis; Protein Synthesis Inhibitors; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Transduction, Genetic; Transfection | 2001 |
Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line.
Topics: Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Survival; DNA, Neoplasm; Etoposide; Humans; In Situ Nick-End Labeling; Kinetics; Lymphoma; Protein Biosynthesis; Signal Transduction; Tumor Cells, Cultured | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, bcl-2; Half-Life; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Polymerase Chain Reaction; Prednisone; Recurrence; Rituximab; Transplantation, Autologous; Vincristine | 2002 |
Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon-gamma; Interleukin-12; Interleukins; Lung Neoplasms; Lymphoma; Male; Middle Aged; Prednisone; Regression Analysis; T-Lymphocytes; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Time Factors; Tissue and Organ Harvesting; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Vincristine | 2002 |
Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Etoposide; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; In Situ Hybridization; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2002 |
Cure in a case of primary hepatic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Liver Neoplasms; Lymphoma; Male; Methotrexate; Prednisolone; Tomography, X-Ray Computed; Vincristine | 2000 |
DNA damage-induced [Zn(2+)](i) transients: correlation with cell cycle arrest and apoptosis in lymphoma cells.
Topics: Apoptosis; Cell Cycle; Chelating Agents; Cytoplasm; DNA Damage; Ethylenediamines; Etoposide; Fluorescent Dyes; Humans; Lymphoma; Nucleic Acid Synthesis Inhibitors; Osmolar Concentration; Quinolones; Subcellular Fractions; Tosyl Compounds; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Zinc | 2002 |
Evaluation of VP-16-213 in malignant lymphoma and melanoma.
Topics: Adult; Drug Evaluation; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma; Male; Melanoma; Podophyllotoxin | 1978 |
Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.
Topics: Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Lymphoma; Neoplasms, Experimental; Podophyllotoxin | 1976 |
Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
Topics: Adult; Ambulatory Care; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins | 1992 |
Penetration of etoposide into human malignant brain tumors after intravenous and oral administration.
Topics: Administration, Oral; Adolescent; Adult; Aged; Brain Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Etoposide; Female; Glioma; Humans; Injections, Intravenous; Lymphoma; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Time Factors | 1992 |
[Recent progress in the chemotherapy program and its theoretical background--malignant lymphoma].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexate; Prednisolone; Survival Rate; Vincristine | 1992 |
Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Component Removal; Blood Transfusion, Autologous; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Male; Middle Aged; Recombinant Proteins | 1992 |
Bone marrow purging in patients with refractory cancer.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Child; Child, Preschool; Colony-Forming Units Assay; Etoposide; Female; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Leukemia; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasms; Transplantation, Autologous | 1992 |
Ablative therapy in bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma | 1991 |
Pneumothorax following cytotoxic chemotherapy in malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Humans; Lung; Lung Neoplasms; Lymphoma; Male; Methotrexate; Middle Aged; Pneumothorax; Prednisone; Procarbazine; Radiography; Vinblastine; Vincristine | 1990 |
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Remission Induction; Survival Rate | 1991 |
Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro.
Topics: Animals; Bleomycin; Drug Synergism; Etoposide; Humans; Indomethacin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipoxygenase Inhibitors; Lung Neoplasms; Lymphoma; Methotrexate; Neoplasms, Experimental; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostaglandins; Protein Kinase Inhibitors; Tumor Cells, Cultured | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoguazone; Mitoxantrone; Remission Induction; Survival Rate | 1991 |
Massively bleeding gastrosplenic fistula following cytostatic chemotherapy of a malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Fistula; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Splenic Diseases; Stomach Neoplasms | 1991 |
Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cell Death; Cell Separation; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Methylprednisolone; Tumor Cells, Cultured | 1991 |
Chronic daily administration of oral etoposide in refractory lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Thrombocytopenia | 1990 |
Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bone Marrow Transplantation; Carcinoma, Non-Small-Cell Lung; Catheterization, Central Venous; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Middle Aged; Neoplasms | 1990 |
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Carmustine; Etoposide; Female; Humans; Injections, Intravenous; Lymphoma; Male; Melanoma; Melphalan; Middle Aged; Time Factors | 1990 |
The results of Vepesid therapy in the treatment of malignant lymphomas.
Topics: Adult; Aged; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged | 1990 |
BVAC ablative chemotherapy followed by autologous bone marrow transplantation for patients with advanced lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Time Factors | 1990 |
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy.
Topics: Acute Disease; Blood Cells; Bone Marrow Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Etoposide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Spleen | 1990 |
In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Topics: Bone Marrow; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Nitrogen Mustard Compounds; Tumor Cells, Cultured | 1990 |
Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Leucovorin; Lomustine; Lung Diseases; Lymphoma; Middle Aged | 1986 |
Hematologic malignancies: non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Leucovorin; Lymphoma; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Vinblastine; Vincristine | 1986 |
The simultaneous presentation of peripheral T-cell lymphoma and hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Head and Neck Neoplasms; Histocytochemistry; HLA-DR Antigens; Humans; Leukemia, Hairy Cell; Lymphatic Metastasis; Lymphoma; Microscopy, Electron; Middle Aged; Prednisone; Procarbazine; Scalp; T-Lymphocytes; Vincristine | 1987 |
Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrow.
Topics: Antineoplastic Agents; B-Lymphocytes; Bleomycin; Bone Marrow; Cell Line; Cell Separation; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Mechlorethamine; Vincristine | 1988 |
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Middle Aged; Prednisolone; Procarbazine | 1989 |
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Endocrine System Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Libido; Lymphoma; Male; Menstruation Disturbances; Middle Aged; Ovarian Diseases; Whole-Body Irradiation | 1989 |
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Gene Expression; Humans; Leukemia; Lymphoma; Membrane Glycoproteins; Mitoxantrone; RNA, Messenger; Tumor Cells, Cultured; Vinblastine; Vincristine; Vindesine | 1989 |
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Vincristine | 1985 |
New conditioning regimens for high risk marrow transplants.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporins; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged | 1989 |
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leucovorin; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Remission Induction; Vincristine | 1989 |
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Topics: Administration, Oral; Biological Availability; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Kinetics; Lung Neoplasms; Lymphoma; Male; Neoplasms; Podophyllotoxin | 1986 |
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Evaluation; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexate; Methylprednisolone; Mitoguazone; Transplantation, Autologous | 1988 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms | 1988 |
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Podophyllotoxin | 1988 |
Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Etoposide; Hematopoiesis; Humans; Ifosfamide; Lymphoma; Middle Aged; Risk Factors | 1988 |
[Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1987 |
Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Topics: Bone Marrow; Bone Marrow Transplantation; Colony-Forming Units Assay; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Microscopy, Electron; Podophyllotoxin; Transplantation, Autologous | 1986 |
In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.
Topics: Carcinoma, Bronchogenic; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Lymphoma; Regression Analysis; Tumor Stem Cell Assay | 1987 |
Etoposide and cisplatinum in resistant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged | 1987 |
[Etoposide in the treatment of recurrent malignant lymphoma].
Topics: Adolescent; Adult; Aged; Etoposide; Hodgkin Disease; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin | 1986 |
[A case of coexisting primary malignant lymphoma and adenocarcinoma of the stomach].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gastrectomy; Gastroscopy; Humans; Lymphoma; Neoplasms, Multiple Primary; Prednisolone; Stomach; Stomach Neoplasms; Vinblastine; Vincristine | 1986 |
Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures.
Topics: Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma | 1987 |
Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate, and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Gallium; Humans; Lymphoma; Middle Aged; Mitoguazone | 1987 |
Results of MIME salvage regimen for recurrent or refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexate; Mitoguazone; Prognosis; Remission Induction | 1987 |
[A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukemia; Lymphoma; Male; Middle Aged; Podophyllotoxin | 1985 |
[VP 16-213].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Humans; Leucovorin; Lymphoma; Methotrexate; Podophyllotoxin; Prednisolone | 1985 |
Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexate; Podophyllotoxin; Recurrence | 1986 |
[Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anorexia; Drug Evaluation; Etoposide; Fatigue; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
[Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia; Lymphoma; Male; Myeloproliferative Disorders; Podophyllotoxin | 1986 |
[ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
Topics: Aclarubicin; Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Naphthacenes; Prednisolone; Thrombocytopenia; Vincristine | 1986 |
A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide.
Topics: Absorption; Chromatography, High Pressure Liquid; Diffusion; Etoposide; Female; Humans; Kinetics; Lymphoma; Middle Aged; Pleural Effusion; Podophyllotoxin | 1985 |
Vindesine, etoposide (VP-16), and prednisolone (VEP) in relapsed patients with grade II non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Prednisolone; Vinblastine; Vindesine | 1985 |
VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Humans; Lymphoma; Middle Aged; Pilot Projects; Podophyllotoxin | 1985 |
[Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Topics: Administration, Oral; Adult; Aged; Capsules; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Podophyllotoxin; Thrombocytopenia | 1985 |
Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Kidney; Lymphoma; Male; Middle Aged | 1985 |
[Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
Topics: Adult; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence | 1985 |